CUI Global announced today that it has closed on its $10 million equity raise with the aid of its U.S. investment banker, Merriman Capital, Inc., and its London advisor, Prosdocimi Ltd. Proceeds of the raise will be used for working capital and to pay down and retire certain corporate debt, as well as to bring the company’s new Vergence, Novum, and Solus Technologies to the market.
This capital infusion and its associated up-list to the Nasdaq Capital Market are momentous events for CUI Global, assuring the company’s plans to move forward with its technology strategy, commercialize its product lines, further broaden its audience, and bring increased value to the company’s shareholders.
CUI Global is a platform company specializing in maximizing shareholder value through acquiring and developing innovative companies and technologies. CUI Global touches many markets through its diversified portfolio of industry-leading technologies – from the energy sector to the networking and telecom industries. For additional information, visit www.cuiglobal.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Wednesday, February 29, 2012
Alvarion Ltd. (ALVR) Unveils New 3G and LTE Mobile Data Offloading Solution
Today, Alvarion announced a new solution for Wi-Fi mobile data offloading in 3G and LTE networks that will enable a high level of service, fast connectivity, and secured Internet access. The company’s carrier-grade Wi-Fi, based on two-way Beamforming Wi-Fi technology, will provide an all-inclusive solution for the scalability, reliability, and security needs of operators with large-scale Wi-Fi networks for mobile data offloading and hot zones.
Operators can now benefit from increased network capacity and high traffic area coverage – where data congestion currently overloads 3G and LTE networks – thanks to Alvarion’s Mobile Data Offloading solution. The solution is Hot Spot and 802.11u ready, which permits a cellular-like experience via the Wi-Fi network with zero-configuration from the user. Operators can utilize the Wi-Fi network for more cost-effective user data connectivity – still providing the same level of service – and expand their network coverage and capacity, returning the original capacity to their 3G/LTE network.
Alvarion’s Mobile Data Offloading solution enables operators to increase network customer retention, minimize churn, and improve customer satisfaction. By using a carrier-grade Wi-Fi solution, operators can gain insight into user behavior by seeing network users and their user information. They can resultantly begin offering revenue-generating services like location-based amenities and mobile advertising; they can also lease extra capacity to service providers.
With the growing abundance of Wi-Fi enabled smartphones, laptops, and tablets, it follows that the same operators should be able to implement a data offload solution that is cost-effective, easy to install, scalable, and utilizes the free unlicensed spectrum. Alvarion’s Wi-Fi technology, closely integrated with the mobile operators’ core network, allows more solutions to be offered to customers addressing their increasing capacity challenges. The idea of merging Wi-Fi and 3G/LTE networks as one network is becoming a reality.
Alvarion provides optimized wireless broadband solutions that address the challenges in connectivity, coverage and capacity experienced by public and private networks. The company’s state-of-the-art solutions are founded upon multiple technologies across both licensed and unlicensed spectrums.
For further information about the company, visit www.alvarion.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Operators can now benefit from increased network capacity and high traffic area coverage – where data congestion currently overloads 3G and LTE networks – thanks to Alvarion’s Mobile Data Offloading solution. The solution is Hot Spot and 802.11u ready, which permits a cellular-like experience via the Wi-Fi network with zero-configuration from the user. Operators can utilize the Wi-Fi network for more cost-effective user data connectivity – still providing the same level of service – and expand their network coverage and capacity, returning the original capacity to their 3G/LTE network.
Alvarion’s Mobile Data Offloading solution enables operators to increase network customer retention, minimize churn, and improve customer satisfaction. By using a carrier-grade Wi-Fi solution, operators can gain insight into user behavior by seeing network users and their user information. They can resultantly begin offering revenue-generating services like location-based amenities and mobile advertising; they can also lease extra capacity to service providers.
With the growing abundance of Wi-Fi enabled smartphones, laptops, and tablets, it follows that the same operators should be able to implement a data offload solution that is cost-effective, easy to install, scalable, and utilizes the free unlicensed spectrum. Alvarion’s Wi-Fi technology, closely integrated with the mobile operators’ core network, allows more solutions to be offered to customers addressing their increasing capacity challenges. The idea of merging Wi-Fi and 3G/LTE networks as one network is becoming a reality.
Alvarion provides optimized wireless broadband solutions that address the challenges in connectivity, coverage and capacity experienced by public and private networks. The company’s state-of-the-art solutions are founded upon multiple technologies across both licensed and unlicensed spectrums.
For further information about the company, visit www.alvarion.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
AxoGen, Inc. (AXGN) is “One to Watch”
AxoGen, Inc., parent company of wholly-owned operating subsidiary AxoGen Corp., is the Alachua, FL, headquartered developer of an impressive portfolio of proprietary technologies in the peripheral nerve reconstruction/regeneration space, which, through advancements like the Avance® Nerve Graft, is revolutionizing peripheral nerve restoration methods. AxoGen is a bold pioneer on the forefront of nerve repair science with thousands of surgical implants of the company’s products performed across the U.S., including in military hospitals, offering patients an alternative to costly, risky autografts (taking nerve tissue from another part of the body).
The sensitive nerve tissues often damaged during traumatic injury (700k plus people in the U.S. each year alone, a roughly $1B potential domestic market), or as a result of surgical intervention procedures, repetitive stress injuries, and chronic compression injuries, can cause serious impairment, including loss of muscle function, sensitivity, neuroma (a growth or tumor of nerve tissue), or chronic pain. AxoGen has devised a host of key technologies, focused on ExtraCellular Matrix (ECM) scaffolds and the associated, proprietary, patent-protected, and licensed decellularization technologies, which allow the host tissue to retain micro-structural integrity, promoting regeneration of tissues via the patient’s own cells/natural cellular activity.
This is a massive boon for sufferers of peripheral nerve damage and AXGN is well-positioned to deliver to an underserved market what is essentially the only complete portfolio of Peripheral Nerve Repair (PNR) products in the space. AXGN has built the team required to execute on their commercialization strategy as well, with over 100 years combined experience in the tissue regeneration field, showing the kind of historic market penetration capability ideal for bringing this compelling value proposition to optimal levels.
Comprising the only complete nerve repair portfolio to both repair and protect peripheral nerves, consisting of a variety of size and length availabilities, these AXGN products help to wrap the nerve or bridge a gap, providing a structure/scaffolding for regrowth, separating/isolating the nerve as necessary from other tissues:
• Avance® Nerve Graft – decellularized/sterile three dimensional ECM processed from human peripheral nerve tissue for bridging gaps in the 15mm to 70 mm range up to 5mm diameter; recently (Jan 16, meaningful recovery achieved in 87% of patients) saw clinical peer-reviewed results published in Jan 2012 issue of Microsurgery where Principal Investigator of the study, Darrell Brooks, M.D., of The Buncke Clinic commented on the findings, that such processed nerve allografts helped patients overcome all the dominant hindering factors associated with peripheral nerve repair
• AxoGuard® Nerve Protector – sterile, single-use wrap for protecting peripheral nerves (or reinforcing a coaptation/partially severed nerve site) up to 40 mm that allows for tissue regrowth and healing thanks to a multi-laminar ECM that separates and shields the nerve from surrounding tissues
• AxoGuard® Nerve Connector – coaptation aid for bridging gaps up to 5mm in a unique 10 mm length format that closely approximates served nerve ends, ideal for coaptation site aligning/connecting of nerves in the sub 5 mm range
So far, the company has only tapped into a tiny fraction of the overall market, and because the company’s business strategy emphasizes a strong R&D pipeline, manufacturing process optimization, and a continual refinement of the core commercialization strategy, the company is primed to engage a national coverage roll out. AxoGen’s current vector has them set to expand national coverage via augmented sales range/support capabilities, driving growth through the same organic, customer-focused and personnel-focused means.
AxoGen is working hard to reinforce this lead position, where products like Avance® Nerve Graft represent the first and only commercially available peripheral nerve allografts for severed nerve gap reconstruction. Diligently expanding the pool of clinical data, working to create the largest multi-center peripheral nerve study so far, the company is even readying for access into prostate/breast reconstruction areas.
For more information on this constant innovator, please visit the AxoGen, Inc. website at www.AxoGenInc.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The sensitive nerve tissues often damaged during traumatic injury (700k plus people in the U.S. each year alone, a roughly $1B potential domestic market), or as a result of surgical intervention procedures, repetitive stress injuries, and chronic compression injuries, can cause serious impairment, including loss of muscle function, sensitivity, neuroma (a growth or tumor of nerve tissue), or chronic pain. AxoGen has devised a host of key technologies, focused on ExtraCellular Matrix (ECM) scaffolds and the associated, proprietary, patent-protected, and licensed decellularization technologies, which allow the host tissue to retain micro-structural integrity, promoting regeneration of tissues via the patient’s own cells/natural cellular activity.
This is a massive boon for sufferers of peripheral nerve damage and AXGN is well-positioned to deliver to an underserved market what is essentially the only complete portfolio of Peripheral Nerve Repair (PNR) products in the space. AXGN has built the team required to execute on their commercialization strategy as well, with over 100 years combined experience in the tissue regeneration field, showing the kind of historic market penetration capability ideal for bringing this compelling value proposition to optimal levels.
Comprising the only complete nerve repair portfolio to both repair and protect peripheral nerves, consisting of a variety of size and length availabilities, these AXGN products help to wrap the nerve or bridge a gap, providing a structure/scaffolding for regrowth, separating/isolating the nerve as necessary from other tissues:
• Avance® Nerve Graft – decellularized/sterile three dimensional ECM processed from human peripheral nerve tissue for bridging gaps in the 15mm to 70 mm range up to 5mm diameter; recently (Jan 16, meaningful recovery achieved in 87% of patients) saw clinical peer-reviewed results published in Jan 2012 issue of Microsurgery where Principal Investigator of the study, Darrell Brooks, M.D., of The Buncke Clinic commented on the findings, that such processed nerve allografts helped patients overcome all the dominant hindering factors associated with peripheral nerve repair
• AxoGuard® Nerve Protector – sterile, single-use wrap for protecting peripheral nerves (or reinforcing a coaptation/partially severed nerve site) up to 40 mm that allows for tissue regrowth and healing thanks to a multi-laminar ECM that separates and shields the nerve from surrounding tissues
• AxoGuard® Nerve Connector – coaptation aid for bridging gaps up to 5mm in a unique 10 mm length format that closely approximates served nerve ends, ideal for coaptation site aligning/connecting of nerves in the sub 5 mm range
So far, the company has only tapped into a tiny fraction of the overall market, and because the company’s business strategy emphasizes a strong R&D pipeline, manufacturing process optimization, and a continual refinement of the core commercialization strategy, the company is primed to engage a national coverage roll out. AxoGen’s current vector has them set to expand national coverage via augmented sales range/support capabilities, driving growth through the same organic, customer-focused and personnel-focused means.
AxoGen is working hard to reinforce this lead position, where products like Avance® Nerve Graft represent the first and only commercially available peripheral nerve allografts for severed nerve gap reconstruction. Diligently expanding the pool of clinical data, working to create the largest multi-center peripheral nerve study so far, the company is even readying for access into prostate/breast reconstruction areas.
For more information on this constant innovator, please visit the AxoGen, Inc. website at www.AxoGenInc.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Ur-Energy Inc. (URG) Completes Acquisition of Interests to Adjacent, Contiguous Acreage in Wyoming at Lost Creek Uranium Property
Today, Ur-Energy, considered by many to be North America’s premier junior uranium mining company, reported that wholly-owned subsidiary NFU Wyoming, LLC successfully completed an important asset exchange agreement with Uranium One Americas, Inc. covering certain federal unpatented mining claims, as well as State of Wyoming Mineral Leases adjacent to the Company’s Lost Creek Property (licensed by the US Nuclear Regulatory Commission and permitted with the Wyoming Department of Environmental Quality).
This agreement provides for the transfer of the property interests, which extend to the N, SE, and SW of the Lost Creek acreage. Post-transaction this agreement will bring the total URG footprint up to a contiguous 39k acres. Tacking on the two Wyoming State Mineral Leases and 175 federal mining claims covered in the agreement adds considerable weight to the already winning strategy employed by URG in Wyoming. An emphasis on the roll front style uranium projects that have abundant in-situ recovery potential has helped URG differentiate its North America strategy from the competition.
President and CEO of URG, Wayne Heili, called it a mutually beneficial scenario for both companies and underscored the congruency of the acquired property interests with the company’s overall regional resource base expansion objectives.
Uranium One will also be providing geologic data on the area associated with the agreement that will serve to flesh-out URG’s existing, massive database of some 1k historic drill holes within the area. The augmented database will serve as a guide for the URG technical team in making determinations about resources for the newly acquired property interests, anticipating an updated NI 43-101 for Lost Creek that will include the new resources.
In consideration, Uranium One stands to acquire a key geologic database with over 3k unique drill hole logs, over 200 report maps and cross-sections that will be instrumental in development of their Allemand-Ross project in the Powder River Basin. The URG Southwest Powder River Basin drill hole database is a superb deal for the company to make in exchange for choice acreage, reinforcing its footprint at a site with a bright future.
Projections for Lost Creek’s development arc look excellent and ongoing planning/permitting positions the company not only for solid production numbers, but will also allow the implementation of 2M lbs per year of in-situ uranium processing infrastructure. Such facilities would augment an already impressive footprint of US/Canadian acreage under URG control.
Uranium mining, especially in highly-accessible markets like the U.S., has drawn increasing interest of late, with the first new U.S. reactors in three decades recently being approved, and global markets shifting more towards fundamentals, raw inputs and materials amid continued sovereign debt concerns. US DOE is also emphasizing smaller, safer reactors and this lays the groundwork for moves like the Bechtel Corp., Babcock, and Wilcox action to exploit their own patents on emergent, next-gen, small modular reactor tech. Indeed, a recent Siemens report indicated it could cost Germany as much as $2T to drop nuclear by 2030, something unthinkable amid persistent concerns over European sovereign debt in particular.
With some 20% of U.S. power coming from nuclear, the attraction of the uranium sector, whose performance has been suppressed since Fukushima (nevertheless essentially returning to performance parity with the S&P), is growing as investors take a closer look at undervalued uranium miners.
For more information on today’s agreement, or to stay up to date with the latest developments at Ur-Energy Inc. please visit the company’s website at www.Ur-Energy.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
This agreement provides for the transfer of the property interests, which extend to the N, SE, and SW of the Lost Creek acreage. Post-transaction this agreement will bring the total URG footprint up to a contiguous 39k acres. Tacking on the two Wyoming State Mineral Leases and 175 federal mining claims covered in the agreement adds considerable weight to the already winning strategy employed by URG in Wyoming. An emphasis on the roll front style uranium projects that have abundant in-situ recovery potential has helped URG differentiate its North America strategy from the competition.
President and CEO of URG, Wayne Heili, called it a mutually beneficial scenario for both companies and underscored the congruency of the acquired property interests with the company’s overall regional resource base expansion objectives.
Uranium One will also be providing geologic data on the area associated with the agreement that will serve to flesh-out URG’s existing, massive database of some 1k historic drill holes within the area. The augmented database will serve as a guide for the URG technical team in making determinations about resources for the newly acquired property interests, anticipating an updated NI 43-101 for Lost Creek that will include the new resources.
In consideration, Uranium One stands to acquire a key geologic database with over 3k unique drill hole logs, over 200 report maps and cross-sections that will be instrumental in development of their Allemand-Ross project in the Powder River Basin. The URG Southwest Powder River Basin drill hole database is a superb deal for the company to make in exchange for choice acreage, reinforcing its footprint at a site with a bright future.
Projections for Lost Creek’s development arc look excellent and ongoing planning/permitting positions the company not only for solid production numbers, but will also allow the implementation of 2M lbs per year of in-situ uranium processing infrastructure. Such facilities would augment an already impressive footprint of US/Canadian acreage under URG control.
Uranium mining, especially in highly-accessible markets like the U.S., has drawn increasing interest of late, with the first new U.S. reactors in three decades recently being approved, and global markets shifting more towards fundamentals, raw inputs and materials amid continued sovereign debt concerns. US DOE is also emphasizing smaller, safer reactors and this lays the groundwork for moves like the Bechtel Corp., Babcock, and Wilcox action to exploit their own patents on emergent, next-gen, small modular reactor tech. Indeed, a recent Siemens report indicated it could cost Germany as much as $2T to drop nuclear by 2030, something unthinkable amid persistent concerns over European sovereign debt in particular.
With some 20% of U.S. power coming from nuclear, the attraction of the uranium sector, whose performance has been suppressed since Fukushima (nevertheless essentially returning to performance parity with the S&P), is growing as investors take a closer look at undervalued uranium miners.
For more information on today’s agreement, or to stay up to date with the latest developments at Ur-Energy Inc. please visit the company’s website at www.Ur-Energy.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Aastrom Biosciences, Inc. (ASTM) to Present at the ROTH Capital Partners 24th Annual Conference
Aastrom Biosciences is a biotech company engaged in developing autologous cell therapies for the treatment of severe and chronic cardiovascular diseases. The company’s clinical development programs include CLI program, which is in phase IIb clinical development for the treatment of serious and advanced stage of peripheral arterial diseases; and its DCM development program, which is in phase II for the treatment of dilated cardiomyopathy (DCM). The company also has two ongoing U.S. phase II trials to investigate surgical and catheter-based delivery for its product in the treatment of DCM. For more information visit the company’s Web site at www.aastrom.com
ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Acacia Research Corp. (ACTG) to Present at the ROTH Capital Partners 24th Annual Conference
Acacia Research operates through its subsidiaries to partner with inventors and patent owners, license the patents to corporate users, and share the revenue. Acacia’s subsidiaries control more than 200 patent portfolios spanning technologies used in a wide variety of industries. For more information visit the company’s Web site at www.acaciaresearch.com
ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Tuesday, February 28, 2012
GlobalWise Investments, Inc. (GWIV) Tells of Intellinetics’ Evolution from ECM Industry Pioneer to Leading-Edge Cloud Technology Company
GlobalWise Investments, Inc. and its wholly owned subsidiary Intellinetics, Inc., a leading-edge technology company focused on the design, implementation and management of cloud-based Enterprise Content Management (“ECM”) systems in both the public and private sectors, today provided an overview of Intellinetics’ history and current position in the ECM industry.
The Intellinetics’ flagship ECM platform, Intellivue™, represents a new industry benchmark in making the promise of ECM a simple to attain, affordable reality by combining the power of the Cloud with on-demand solution templates and user-focused design. Intellivue™ provides clients with the ability to access and manage every piece of content they produce or receive, including but not limited to paper documents, digital content, database print streams and e-mail. The data is accessible from virtually any PC, laptop, tablet or smartphone from anywhere in the world.
Through its cloud-based Intellivue™ product line and unique Channel / OEM distribution model, Intellinetics is prepared to dominate in the underserved small-to-mid sized business marketplace. The Company’s position reflects the entrepreneurial vision and innovation of its founders, which served as catalysts for Intellinetics’ evolution from an early pioneer to a recognizable player in the ECM industry.
In 1994, father and son founders Michael and Matthew Chretien formed Intellinetics, Inc. in Columbus, Ohio. Leveraging Michael’s 25-year law enforcement career combined with Matthew’s IT and operational backgrounds, Intellinetics provided IT consulting, document storage systems and project-specific software development. In 1995, the entrepreneurs won their first consulting contract with the Ohio State Highway Patrol to provide a more sophisticated solution to their 1950s era records management system. This marked the beginning of the modern-day Intellinetics, which began to transition itself from records content storage consulting toward becoming a software development firm focused on enterprise-wide content management.
From mid-1990 to early 2000, Intellinetics focused on business “intelligence” and developed industry-first redaction-enabled technology for the Ohio State Highway Patrol, a development that garnered national recognition. This new redaction-enabled software won the Technology Award of Excellence and continued the Company’s software development path toward an ECM system that could be used as an enterprise-wide document management solution. During this formation timeframe, the Intellinetics customer base evolved beyond law enforcement to government contracts and commercial clients.
From 2001 through 2007, Intellinetics continued to focus on software development, refinement, customer expansion and increasing sales. From 2007 through the beginning of 2010, Intellinetics was awarded two Ohio Innovation Loans to accelerate its software migration from a more traditional client-server premise-based solution to Web-based services optimized for cloud delivery. This transformation is foundational to Intellinetics’ success and timing. As the proliferation of “smartphone” mobile devices were becoming a more viable business tool, the Intellinetics software was being optimized for access from any Internet-enabled hardware device.
Today, with the Company’s technology migration to the “cloud” complete, Intellinetics is rapidly becoming an aggressive player in the growing ECM industry, which Gartner estimates will exceed $5.7 billion by 2014 with compounded annual growth rates of 10.1%. The Intellivue™ ECM platform is now being distributed through a variety of direct sales and value-added resellers or channels throughout the private and public sectors. Leveraging its industry leading position, Intellinetics will capture emerging growth opportunities by driving the ECM economic benefits to the private and public sectors in the underserved small-to-mid sized business market.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The Intellinetics’ flagship ECM platform, Intellivue™, represents a new industry benchmark in making the promise of ECM a simple to attain, affordable reality by combining the power of the Cloud with on-demand solution templates and user-focused design. Intellivue™ provides clients with the ability to access and manage every piece of content they produce or receive, including but not limited to paper documents, digital content, database print streams and e-mail. The data is accessible from virtually any PC, laptop, tablet or smartphone from anywhere in the world.
Through its cloud-based Intellivue™ product line and unique Channel / OEM distribution model, Intellinetics is prepared to dominate in the underserved small-to-mid sized business marketplace. The Company’s position reflects the entrepreneurial vision and innovation of its founders, which served as catalysts for Intellinetics’ evolution from an early pioneer to a recognizable player in the ECM industry.
In 1994, father and son founders Michael and Matthew Chretien formed Intellinetics, Inc. in Columbus, Ohio. Leveraging Michael’s 25-year law enforcement career combined with Matthew’s IT and operational backgrounds, Intellinetics provided IT consulting, document storage systems and project-specific software development. In 1995, the entrepreneurs won their first consulting contract with the Ohio State Highway Patrol to provide a more sophisticated solution to their 1950s era records management system. This marked the beginning of the modern-day Intellinetics, which began to transition itself from records content storage consulting toward becoming a software development firm focused on enterprise-wide content management.
From mid-1990 to early 2000, Intellinetics focused on business “intelligence” and developed industry-first redaction-enabled technology for the Ohio State Highway Patrol, a development that garnered national recognition. This new redaction-enabled software won the Technology Award of Excellence and continued the Company’s software development path toward an ECM system that could be used as an enterprise-wide document management solution. During this formation timeframe, the Intellinetics customer base evolved beyond law enforcement to government contracts and commercial clients.
From 2001 through 2007, Intellinetics continued to focus on software development, refinement, customer expansion and increasing sales. From 2007 through the beginning of 2010, Intellinetics was awarded two Ohio Innovation Loans to accelerate its software migration from a more traditional client-server premise-based solution to Web-based services optimized for cloud delivery. This transformation is foundational to Intellinetics’ success and timing. As the proliferation of “smartphone” mobile devices were becoming a more viable business tool, the Intellinetics software was being optimized for access from any Internet-enabled hardware device.
Today, with the Company’s technology migration to the “cloud” complete, Intellinetics is rapidly becoming an aggressive player in the growing ECM industry, which Gartner estimates will exceed $5.7 billion by 2014 with compounded annual growth rates of 10.1%. The Intellivue™ ECM platform is now being distributed through a variety of direct sales and value-added resellers or channels throughout the private and public sectors. Leveraging its industry leading position, Intellinetics will capture emerging growth opportunities by driving the ECM economic benefits to the private and public sectors in the underserved small-to-mid sized business market.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Delcath Systems, Inc. (DCTH) Announces First Use of CHEMOSAT® Delivery System
Yesterday, Delcath Systems announced that the Delcath Hepatic CHEMOSAT® Delivery System has been used on first patients at the Johann Wolfgang Goethe University Hospital in Germany. The cases were treated as part of the initial launch and training agreement between Delcath and the hospital.
“Delcath’s partnership with J.W. Goethe reinforces the potential of CHEMOSAT,” said Eamonn P. Hobbs, president and CEO of Delcath. “We recently treated our first patients in Milan and are eager to continue our expansion across Europe. Opening another CHEMOSAT treatment center and treating patients in the continent’s largest market is another step forward in the commercialization of this technology.”
Two patients were treated for inoperable, liver-dominant metastases; one from cutaneous melanoma and one from breast cancer. The treating physicians reported that both patients were treated successfully without procedure-related complications. Delcath is a pharmaceutical and medical device company that specializes in oncology. Delcath’s proprietary systems administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, as well as control the systemic exposure of those agents to the body.
Dr. Thomas J. Vogl, Director of the Institute for Diagnostic and Interventional Radiology at J.W. Goethe, said, “We believe this technology has significant potential to help control cancers in the liver. We’re pleased to be the first cancer center to begin offering this important treatment option to patients in Germany, and are eager to further explore its role in the treatment of multiple tumor types including breast cancer.”
Delcath’s initial focus is on the treatment of primary and metastatic liver cancers. The company obtained authorization to affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011. The CE mark allows the Company to market and sell the CHEMOSAT system in Europe. Delcath has not yet received FDA approval for commercial sale of its system in the United States; currently, the company is preparing for NDA submission and intends to seek FDA approval for commercial sale of its chemosaturation system.
For more information, please visit the company’s website at www.delcath.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“Delcath’s partnership with J.W. Goethe reinforces the potential of CHEMOSAT,” said Eamonn P. Hobbs, president and CEO of Delcath. “We recently treated our first patients in Milan and are eager to continue our expansion across Europe. Opening another CHEMOSAT treatment center and treating patients in the continent’s largest market is another step forward in the commercialization of this technology.”
Two patients were treated for inoperable, liver-dominant metastases; one from cutaneous melanoma and one from breast cancer. The treating physicians reported that both patients were treated successfully without procedure-related complications. Delcath is a pharmaceutical and medical device company that specializes in oncology. Delcath’s proprietary systems administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, as well as control the systemic exposure of those agents to the body.
Dr. Thomas J. Vogl, Director of the Institute for Diagnostic and Interventional Radiology at J.W. Goethe, said, “We believe this technology has significant potential to help control cancers in the liver. We’re pleased to be the first cancer center to begin offering this important treatment option to patients in Germany, and are eager to further explore its role in the treatment of multiple tumor types including breast cancer.”
Delcath’s initial focus is on the treatment of primary and metastatic liver cancers. The company obtained authorization to affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011. The CE mark allows the Company to market and sell the CHEMOSAT system in Europe. Delcath has not yet received FDA approval for commercial sale of its system in the United States; currently, the company is preparing for NDA submission and intends to seek FDA approval for commercial sale of its chemosaturation system.
For more information, please visit the company’s website at www.delcath.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
SoundBite Communications, Inc. (SDBT) Acquires 2ergo Americas
SoundBite Communications recently announced the acquisition of mobile marketing company 2ergo Americas, a subsidiary of 2ergo Group plc. Obtaining 2ergo broadens SoundBite’s base of clients and the mobile marketing services the company offers.
SoundBite provides cloud-based marketing communications focused on two markets: hosted contact centers and mobile marketing, with existing clients including Global 500 and Fortune 500 companies, while facilitating 2 billion customer interactions annually. 2ergo’s marketing clients include Fox News, Fox Sports, the Australian Broadcasting Corporation, U.S. Cellular, Orange, Aviva, and Fidelity, among others.
With 2ergo, SoundBite will receive the ability to provide services such as SMS, mobile coupons, QR code, and mobile web platforms, as well as carrier-grade scalability and Latin American connectivity. SoundBite will also become an authorized reseller of podfi, 2ergo’s contactless redemption and in-store location service. Furthermore, 2ergo Group will become a reseller for SoundBite Engage and SoundBite Insight products, a communications platform and demographic data collection system, respectively.
Jim Milton, president and CEO of SoundBite Communications, said, “We are excited to add the clients, technology and employees of 2ergo Americas to the SoundBite family. This acquisition, combined with the 2ergo Group strategic relationship, will help establish SoundBite as a top player in mobile marketing. We are committed to our mission of enabling clients to harness the power and ubiquity of the mobile device to establish lifelong profitable customer relationships, and we will continue to invest in achieving this goal.”
“Today’s announcement with SoundBite accelerates 2ergo Group’s mobile leadership strategy in three ways,” commented Neale Graham, founder and CEO of 2ergo Group. “First, the proceeds from the sale of 2ergo Americas will help accelerate our podifi development efforts. Second, while we increase our focus on podifi, we are delighted that, in SoundBite, we found a home for our Americas’ clients and a staff that shares our values and passion for client success. And finally, the strategic relationship allows both parties to leverage each others’ best-in-class technology.”
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
SoundBite provides cloud-based marketing communications focused on two markets: hosted contact centers and mobile marketing, with existing clients including Global 500 and Fortune 500 companies, while facilitating 2 billion customer interactions annually. 2ergo’s marketing clients include Fox News, Fox Sports, the Australian Broadcasting Corporation, U.S. Cellular, Orange, Aviva, and Fidelity, among others.
With 2ergo, SoundBite will receive the ability to provide services such as SMS, mobile coupons, QR code, and mobile web platforms, as well as carrier-grade scalability and Latin American connectivity. SoundBite will also become an authorized reseller of podfi, 2ergo’s contactless redemption and in-store location service. Furthermore, 2ergo Group will become a reseller for SoundBite Engage and SoundBite Insight products, a communications platform and demographic data collection system, respectively.
Jim Milton, president and CEO of SoundBite Communications, said, “We are excited to add the clients, technology and employees of 2ergo Americas to the SoundBite family. This acquisition, combined with the 2ergo Group strategic relationship, will help establish SoundBite as a top player in mobile marketing. We are committed to our mission of enabling clients to harness the power and ubiquity of the mobile device to establish lifelong profitable customer relationships, and we will continue to invest in achieving this goal.”
“Today’s announcement with SoundBite accelerates 2ergo Group’s mobile leadership strategy in three ways,” commented Neale Graham, founder and CEO of 2ergo Group. “First, the proceeds from the sale of 2ergo Americas will help accelerate our podifi development efforts. Second, while we increase our focus on podifi, we are delighted that, in SoundBite, we found a home for our Americas’ clients and a staff that shares our values and passion for client success. And finally, the strategic relationship allows both parties to leverage each others’ best-in-class technology.”
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
AdCare Health Systems, Inc. (ADK) Announces Upcoming Presentation at the ROTH Capital Partners 24th Annual Conference
AdCare Health Systems, Inc., a nursing home and assisted living company, today told investors that it will be presenting at the ROTH Capital Partners 24th Annual Conference. The conference will be held at The Ritz Carlton in Laguna Niguel, California, on March 12-14, 2012.
AdCare CEO Boyd Gentry and Chief Acquisition Officer Chris Brogdon are scheduled to present on Monday, March 12, 2012 at 12:00 p.m. Pacific time, and will have one-on-one meetings throughout the day. They will talk about the emerging opportunities in the highly fragmented health care segments of senior assisted living and elderly nursing care.
Mr. Gentry and Mr. Brogdon will also discuss the progress of AdCare’s M&A program designed to build upon its strong reputation for operational efficiency and high-quality living environments. With the recent acquisition of a skilled nursing and assisted living community in Ohio, plus 25 additional skilled nursing centers AdCare has signed and expects to acquire in the first half of 2012, the company’s annualized revenue run-rate is expected to exceed $355 million, which would represent an increase of 570% over revenues in 2010.
Investors unable to attend may view a live feed of the presentation via http://wsw.com/webcast/roth26/adk. A replay will also be available following the conference in the investor relations section of AdCare’s Web site at www.adcarehealth.com.
For more information about the conference, visit http://www.roth.com/main/page.aspx?PageID=7250
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
AdCare CEO Boyd Gentry and Chief Acquisition Officer Chris Brogdon are scheduled to present on Monday, March 12, 2012 at 12:00 p.m. Pacific time, and will have one-on-one meetings throughout the day. They will talk about the emerging opportunities in the highly fragmented health care segments of senior assisted living and elderly nursing care.
Mr. Gentry and Mr. Brogdon will also discuss the progress of AdCare’s M&A program designed to build upon its strong reputation for operational efficiency and high-quality living environments. With the recent acquisition of a skilled nursing and assisted living community in Ohio, plus 25 additional skilled nursing centers AdCare has signed and expects to acquire in the first half of 2012, the company’s annualized revenue run-rate is expected to exceed $355 million, which would represent an increase of 570% over revenues in 2010.
Investors unable to attend may view a live feed of the presentation via http://wsw.com/webcast/roth26/adk. A replay will also be available following the conference in the investor relations section of AdCare’s Web site at www.adcarehealth.com.
For more information about the conference, visit http://www.roth.com/main/page.aspx?PageID=7250
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
AxoGen, Inc. (AXGN) Sees Success with Nerve Regeneration
In January, Dr. Darrell Brooks, a plastic surgeon with The Buncke Clinic in San Francisco, commented on a study, just released at that time, in which he was the principal investigator. The study indicated that Avance® Nerve Graft, a product of AxoGen, achieved meaningful recovery in 87% of patients with peripheral nerve injuries. Why is this significant? According to Dr. Brooks:
“It is commonly accepted among surgeons who do peripheral nerve repair that success of surgery depends on the type of injury, length of nerve discontinuity, the patient’s age and the type of nerve. Our study findings show that with processed nerve allograft, patients can have meaningful recovery regardless of these factors. Based on our findings, the information I use to counsel my patients prior to surgery will change — this is a paradigm shift.”
It’s a good example of the potential of AxoGen technologies. The company is an emerging regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration. Peripheral nerves are critical nerves that provide pathways for motor as well as sensory signals throughout the body. Damage to peripheral nerves can mean a serious loss of feeling and functionality. AxoGen has developed and licensed patented and patent-pending technologies for improving surgical reconstruction and regeneration of peripheral nerves.
AxoGen believes that Avance Nerve Graft is the first and only commercially available allograft nerve for bridging nerve discontinuities (a gap created when the nerve is severed). Avance Nerve Graft is processed from human peripheral nerve tissue, based on AxoGen’s guiding principal that the human body offers the optimal nerve structure. Like other AxoGen products, Avance Nerve Graft has important advantages:
• Applies to long and short gap nerve injuries
• Decellularized and cleansed extracellular matrix
• Provides a three dimensional scaffold (preserving the inherent and relevant structural characteristics of nerve) for bridging a nerve gap
• Structurally supports the body’s own regeneration process
• No donor nerve surgery, therefore no loss of donor nerve function
• Handles similar to an autograft: flexible and pliable
• Alleviates tension at the repair site
• Three years shelf life (kept frozen at or below -40° C/F)
• Supplied sterile in lengths of 15mm to 70 mm and diameters up to 5mm
The company has a rich pipeline of new products to change the standard of care for patients with peripheral nerve injuries. Other AxoGen products include AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector, which protects nerves during the body’s healing process after surgery.
For more information, see the company website at www.AxoGenInc.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“It is commonly accepted among surgeons who do peripheral nerve repair that success of surgery depends on the type of injury, length of nerve discontinuity, the patient’s age and the type of nerve. Our study findings show that with processed nerve allograft, patients can have meaningful recovery regardless of these factors. Based on our findings, the information I use to counsel my patients prior to surgery will change — this is a paradigm shift.”
It’s a good example of the potential of AxoGen technologies. The company is an emerging regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration. Peripheral nerves are critical nerves that provide pathways for motor as well as sensory signals throughout the body. Damage to peripheral nerves can mean a serious loss of feeling and functionality. AxoGen has developed and licensed patented and patent-pending technologies for improving surgical reconstruction and regeneration of peripheral nerves.
AxoGen believes that Avance Nerve Graft is the first and only commercially available allograft nerve for bridging nerve discontinuities (a gap created when the nerve is severed). Avance Nerve Graft is processed from human peripheral nerve tissue, based on AxoGen’s guiding principal that the human body offers the optimal nerve structure. Like other AxoGen products, Avance Nerve Graft has important advantages:
• Applies to long and short gap nerve injuries
• Decellularized and cleansed extracellular matrix
• Provides a three dimensional scaffold (preserving the inherent and relevant structural characteristics of nerve) for bridging a nerve gap
• Structurally supports the body’s own regeneration process
• No donor nerve surgery, therefore no loss of donor nerve function
• Handles similar to an autograft: flexible and pliable
• Alleviates tension at the repair site
• Three years shelf life (kept frozen at or below -40° C/F)
• Supplied sterile in lengths of 15mm to 70 mm and diameters up to 5mm
The company has a rich pipeline of new products to change the standard of care for patients with peripheral nerve injuries. Other AxoGen products include AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector, which protects nerves during the body’s healing process after surgery.
For more information, see the company website at www.AxoGenInc.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Stamps.com, Inc. (STMP) is “One to Watch”
Stamps.com is a name which has become synonymous with USPS® printable postage to many businesses and consumers. The Web site is widely known for providing the simple, affordable, and extremely convenient PC Postage service that lets users generate precise letter, package, and parcel post labels using an ordinary inkjet/laser printer. Granting customers unprecedented service, STMP has built an impressive reputation in just over a decade and a half.
Since its inception in 1996, Stamps.com has continued to pioneer and innovate within the digital postage space, offering new features and services to make the entire process easier, and gaining market share all the while. Brilliant offerings like the PhotoStamps™ product that lets users turn their digital photos, designs, or corporate logos into functional US postage, helps companies deliver more effective overall branding (and lets users add a familiar touch to correspondence).
The obvious benefits of cost for the majority of users, not to mention the time and effort expended simply effecting traditional means, are amazingly dwarfed by the huge savings businesses can achieve over postage meters. Slashing costs over postage meters by as much as half or more, with total reliability, no multi-year leases to sign and a low, $15.99/month flat rate, the Stamps.com solution also delivers total information environment awareness and allows customers to simply use their own computer and printer (no maintenance fees, no proprietary inks, etc.).
One of the less talked about, but certainly key aspects of this model for users is the robust backend framework and additional tools enabled, in addition to the peace of mind that comes with the added user-level control security. Being able to print postage is cheap and easy, but having complete visibility across the business to see how every penny is being spent via an intuitive, extremely granular Stamps.com Enterprise software dashboard is the kind of thing that can be a real game-changer for thriving businesses.
The company recently proved to investors, yet again, that the STMP model is a powerful revenue vehicle, reporting record Q4 FY11 revenue growth of 27% for Core PC Postage over the same quarter in 2010 ($24.5M). Also among Q4 highlights was the 20% jump in overall revenue ($27.2M) and net income of $13.4M, or $0.81 per fully diluted share.
Core PC Postage continues to be a strong revenue vehicle for STMP, and growth in this segment represents an accelerating trend among consumers, reinforced by the proliferation of printing infrastructure amid the swell of migrations to a more digital space, especially among businesses and enterprise customers who do high volume shipping. E-commerce shipping has never been easier and STMP even has seamless MS Word® and QuickBooks® integration, allowing users to print postage right from the software. Stamps.com also lets you import existing address books from Outlook and other popular platforms.
With Stamps.com, users can also take advantage of discounts they’d never see at the post office and track packages with the click of a button. It is not hard to figure out what the buzz is about here, more and more companies are modernizing and upgrading their overall implementation, and transforming the shipping methodology is often central, especially for entities that do a lot of shipping. Automatic integration with Amazon.com®, eBay®, Paypal®, Etsy®, Yahoo!, Google Checkout™, and even user site-specific shopping carts means never having to fill out forms manually and the ability to batch print multiple labels.
STMP continues to put effort into other Non-core PC Postage revenue channels as well, engaging overdrive in the enhanced promotion program for instance, allowing marketing partners to wow customers with direct promotions online. This kind of customer-centric fan service is part of the winning STMP solution, as the company has always striven to make the customer feel comfortable, secure, and at home. The ability for even a small business to effortlessly transform its shipping and outgoing mail into a much more professional looking and feeling format is powerful, and not having to interact with archaic means/modes is something that can really be felt in the bottom line.
Click, print, and mail for massive savings while controlling waste, abuse, or overspending, all within a secure, digital environment that allows for total information awareness and enterprise-wide process transparency. The service provided by STMP is exemplary, starting with a white glove corporate roll-out program that carefully, thoroughly, and seamlessly helps the business transition its infrastructure to Stamps.com.
For more information on Stamps.com Inc. please visit the company’s website at: www.Stamps.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Since its inception in 1996, Stamps.com has continued to pioneer and innovate within the digital postage space, offering new features and services to make the entire process easier, and gaining market share all the while. Brilliant offerings like the PhotoStamps™ product that lets users turn their digital photos, designs, or corporate logos into functional US postage, helps companies deliver more effective overall branding (and lets users add a familiar touch to correspondence).
The obvious benefits of cost for the majority of users, not to mention the time and effort expended simply effecting traditional means, are amazingly dwarfed by the huge savings businesses can achieve over postage meters. Slashing costs over postage meters by as much as half or more, with total reliability, no multi-year leases to sign and a low, $15.99/month flat rate, the Stamps.com solution also delivers total information environment awareness and allows customers to simply use their own computer and printer (no maintenance fees, no proprietary inks, etc.).
One of the less talked about, but certainly key aspects of this model for users is the robust backend framework and additional tools enabled, in addition to the peace of mind that comes with the added user-level control security. Being able to print postage is cheap and easy, but having complete visibility across the business to see how every penny is being spent via an intuitive, extremely granular Stamps.com Enterprise software dashboard is the kind of thing that can be a real game-changer for thriving businesses.
The company recently proved to investors, yet again, that the STMP model is a powerful revenue vehicle, reporting record Q4 FY11 revenue growth of 27% for Core PC Postage over the same quarter in 2010 ($24.5M). Also among Q4 highlights was the 20% jump in overall revenue ($27.2M) and net income of $13.4M, or $0.81 per fully diluted share.
Core PC Postage continues to be a strong revenue vehicle for STMP, and growth in this segment represents an accelerating trend among consumers, reinforced by the proliferation of printing infrastructure amid the swell of migrations to a more digital space, especially among businesses and enterprise customers who do high volume shipping. E-commerce shipping has never been easier and STMP even has seamless MS Word® and QuickBooks® integration, allowing users to print postage right from the software. Stamps.com also lets you import existing address books from Outlook and other popular platforms.
With Stamps.com, users can also take advantage of discounts they’d never see at the post office and track packages with the click of a button. It is not hard to figure out what the buzz is about here, more and more companies are modernizing and upgrading their overall implementation, and transforming the shipping methodology is often central, especially for entities that do a lot of shipping. Automatic integration with Amazon.com®, eBay®, Paypal®, Etsy®, Yahoo!, Google Checkout™, and even user site-specific shopping carts means never having to fill out forms manually and the ability to batch print multiple labels.
STMP continues to put effort into other Non-core PC Postage revenue channels as well, engaging overdrive in the enhanced promotion program for instance, allowing marketing partners to wow customers with direct promotions online. This kind of customer-centric fan service is part of the winning STMP solution, as the company has always striven to make the customer feel comfortable, secure, and at home. The ability for even a small business to effortlessly transform its shipping and outgoing mail into a much more professional looking and feeling format is powerful, and not having to interact with archaic means/modes is something that can really be felt in the bottom line.
Click, print, and mail for massive savings while controlling waste, abuse, or overspending, all within a secure, digital environment that allows for total information awareness and enterprise-wide process transparency. The service provided by STMP is exemplary, starting with a white glove corporate roll-out program that carefully, thoroughly, and seamlessly helps the business transition its infrastructure to Stamps.com.
For more information on Stamps.com Inc. please visit the company’s website at: www.Stamps.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
BofI Holding, Inc. (BOFI) Gets “Buy” Rating from Sidoti
In January, BofI Holding, parent company of Bank of Internet USA, announced that CFO Andrew Micheletti was going to present at the Sidoti & Company, LLC, Semiannual New York Micro-Cap Conference held on January 10. It was a good time to present, given BofI’s earlier release of second quarter financial results, showing net income growth of just over 35% from the same quarter of the previous year.
BofI is known as a “branchless bank”, operating via state-of-the-art online banking technology versus traditional brick-and-mortar branches, allowing BofI customers to bank using mobile applications as well as standard browsers. Headquartered in San Diego, California, but serving personal, commercial, and industrial customers throughout the country, they now carry $2 billion in assets. The company aims to become “the most innovative branchless bank in the United States providing products and services superior to our competitors, branch-based or otherwise.” BofI specializes in income property lending, providing multi-family housing loans and some commercial property lending, in addition to a wide range of home lending products. They also do bulk loan pool acquisitions, C&I loans, structured finance, mortgage loan trading, and secondary marketing/loan sales.
It’s a model that has worked well for BofI, reducing operating costs for the bank while maximizing service availability for customers. BofI’s revenues have grown rapidly to over $100 million, from only $23 million in 2005. With net income up 35%, total deposits up 39%, non-performing assets down from 80 basis points to 64 basis points, and a strong mortgage loan pipeline, BofI anticipates a record 2012. It’s all good information to take to the investment community. In Sidoti’s case, it must have worked. The New York based equities research firm just initiated coverage with a “Buy” rating.
For more information, see the company website at www.BOFIFederalBank.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
BofI is known as a “branchless bank”, operating via state-of-the-art online banking technology versus traditional brick-and-mortar branches, allowing BofI customers to bank using mobile applications as well as standard browsers. Headquartered in San Diego, California, but serving personal, commercial, and industrial customers throughout the country, they now carry $2 billion in assets. The company aims to become “the most innovative branchless bank in the United States providing products and services superior to our competitors, branch-based or otherwise.” BofI specializes in income property lending, providing multi-family housing loans and some commercial property lending, in addition to a wide range of home lending products. They also do bulk loan pool acquisitions, C&I loans, structured finance, mortgage loan trading, and secondary marketing/loan sales.
It’s a model that has worked well for BofI, reducing operating costs for the bank while maximizing service availability for customers. BofI’s revenues have grown rapidly to over $100 million, from only $23 million in 2005. With net income up 35%, total deposits up 39%, non-performing assets down from 80 basis points to 64 basis points, and a strong mortgage loan pipeline, BofI anticipates a record 2012. It’s all good information to take to the investment community. In Sidoti’s case, it must have worked. The New York based equities research firm just initiated coverage with a “Buy” rating.
For more information, see the company website at www.BOFIFederalBank.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Limelight Networks, Inc. (LLNW) Helps Wayfair.com Optimize Site and Drive Online Conversions
Located in Tempe, Arizona, Limelight Networks provides solutions that enable business and technology decision makers to profit from the shift of content and advertising to the online world. Today, Limelight announced the completion of Limelight Accelerate on Wayfair.com and Allmodern.com.
Limelight has garnered attention by proactively optimizing Web sites for most of the retailers attending eTail Palm Springs. The front-end optimization solution (FEO) improves Time to Action – the time it takes visitors to first engage with content on online sites. The solution has been shown in comprehensive testing to boost performance on most Web sites twofold to fivefold.
Leading the team at Wayfair LLC, formerly CSN Store, is Steven Conine whom is the Co-Founder and Chairman. In reference to this press release, Conine stated, “Online shoppers don’t want to wait–they want to engage and interact with sites instantly. We knew that our sites could have a stronger impact if we delivered the most important and desired content first. Because our Web properties generate dynamic content to enable unique and customized experiences for our customers, we required a solution that could optimize dynamic content on the fly–Limelight Accelerate delivered this capability for us. After just one month of employing Accelerate, we saw a 17% jump in page views per visitor. It’s clear that our improved site performance created a more satisfying shopping experience for our customers, which ultimately affects our brand and our bottom line.”
Limelight Networks Senior Vice President David Hatfield added, “Limelight Accelerate ensures that the most important information renders first, so content such as specific product details are prioritized. The faster users get the information they want, the faster they will act on it, resulting in longer site visits, more sales, and ultimately enhanced brand loyalty.”
Currently, Limelight Networks, Inc. is trading in the $3.95 range. To learn more about this press release or the company as a whole, visit their corporate website at www.limelight.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Limelight has garnered attention by proactively optimizing Web sites for most of the retailers attending eTail Palm Springs. The front-end optimization solution (FEO) improves Time to Action – the time it takes visitors to first engage with content on online sites. The solution has been shown in comprehensive testing to boost performance on most Web sites twofold to fivefold.
Leading the team at Wayfair LLC, formerly CSN Store, is Steven Conine whom is the Co-Founder and Chairman. In reference to this press release, Conine stated, “Online shoppers don’t want to wait–they want to engage and interact with sites instantly. We knew that our sites could have a stronger impact if we delivered the most important and desired content first. Because our Web properties generate dynamic content to enable unique and customized experiences for our customers, we required a solution that could optimize dynamic content on the fly–Limelight Accelerate delivered this capability for us. After just one month of employing Accelerate, we saw a 17% jump in page views per visitor. It’s clear that our improved site performance created a more satisfying shopping experience for our customers, which ultimately affects our brand and our bottom line.”
Limelight Networks Senior Vice President David Hatfield added, “Limelight Accelerate ensures that the most important information renders first, so content such as specific product details are prioritized. The faster users get the information they want, the faster they will act on it, resulting in longer site visits, more sales, and ultimately enhanced brand loyalty.”
Currently, Limelight Networks, Inc. is trading in the $3.95 range. To learn more about this press release or the company as a whole, visit their corporate website at www.limelight.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Monday, February 27, 2012
VistaGen Therapeutics (VSTA): A Hidden Stem Cell Opportunity
When it comes to modern medicine, stem cells are seen as playing a role unmatched by anything else. Used in a growing number of cell therapies for certain cancers, various diseases related to the immune system, and other treatment applications, in addition to cell research, stem cell technology is opening an increasing number of doors for medical researchers and practitioners. Today it’s a market rapidly closing in on $1 billion, and, in spite of controversy surrounding some aspects of stem cell use, the funding for stem cell research continues to grow.
Stem cells, including pluripotent stem cells (non-embryonic adult cells that are artificially reprogrammed to mimic embryonic stem cells), are unique in their ability to differentiate into specialized cells, such as heart or muscle or nerve cells. As a result, they provide an important tool for medical research, treatment, and drug development.
For example, stem cells can play a substantial role in the discovery of new medicines that are more effective and safer for patients. They can also be used in the field of regenerative medicine, where various tissues and organs can be generated to replace damaged ones, for application to spinal cord injuries, Parkinson’s disease, diabetes, and perhaps even Alzheimer’s. In addition, given their ability to duplicate the functions of a whole host of other cells, stem cells are becoming important in all types of advanced biomedical research, helping us understand the most basic workings of the human cell and human body.
But one of the lesser known, though potentially huge applications of stem cell technology, involves the early stage testing of drug candidates. The pharmaceutical industry can spend vast amounts of money developing and introducing a new drug, only to find out later that it has negative effects on the heart, liver, or other organs. As a result, the drug must be limited or withdrawn, greatly reducing, or even eliminating, the anticipated profit potential. The numbers involved are telling. It can cost over $1 billion to bring a new drug to market, and it can all be lost if the drug is later found to have toxicity issues, such as causing heart problems. In addition to the time and money spent on developing and marketing, companies can face a long string of associated lawsuits.
In the case of Avandia, an anti-diabetic drug produced by GlaxoSmithKline, concerns that the drug may lead to an increased risk of heart attack, even though not firmly established at the time, still led to a major reduction in sales, and a slew of lawsuits. Given that the drug had been bringing in over $2 billion in annual sales prior to the trouble, it was a significant blow, and gives an idea of how much big pharma might be willing to pay for a workable solution.
It’s a problem for which California based VistaGen Therapeutics believes it has the answer, and it all revolves around stem cells. Using advanced stem cell technology, VistaGen has produced functional human cardiac cells that can be used early on in the drug development process to test for cardiotoxicity. Cardiotoxicity has been a factor in over 30% of drug withdrawals, and addressing it is seen as a major market. The use of real human heart cells in pre-clinical testing offers important advantages over traditional testing methods, such as animal testing.
First of all, it can be performed at the earliest stages of development, reducing the risks of developing the wrong drug. It’s also more accurate, since traditional testing involving animals can fail to detect potential risks in humans. And it’s far easier than the large number of patients and lengthy testing required in human trials. By identifying cardiotoxicity issues early in the process, drug developers can take steps to rescue the drug candidate, developing variants that are both functional and safe. Given that stem cells, including non-embryonic stem cells, can be pointed in many different directions, their potential to transform drug development has no clear limit.
But VistaGen is only now beginning to show up on many investors’ radar screens. Its recent strategic drug rescue-related collaboration agreements with Synterys, a medicinal chemistry and drug discovery services company, and Cato Research Ltd., a leading contract research and development organization, were further indications of the recognition VistaGen has earned for the exciting potential of its stem cell technology-based drug rescue initiatives.
The collaborations are intended to help develop safer drug rescue variants by leveraging VistaGen’s drug rescue initiatives with Synterys’ medicinal chemistry expertise and Cato Research’s drug development and regulatory capabilities. In the case of its key collaboration with Synterys, the idea is to combine VistaGen’s human pluripotent stem cell technology platform, called Human Clinical Trials in a Test TubeTM, with modern medicinal chemistry, to generate new safer variants of once-promising drug candidates discontinued in development due to heart toxicity concerns.
VistaGen sees itself as essentially transforming drug development by bring human biology to the front end of the process, attacking cardiotoxicity issues early in the cost curve, and removing much of the risk and uncertainty typically involved in bringing new drugs to market. Perhaps more importantly, it lessens the chance that patients will be asked to play the role of unsuspecting guinea pig, taking drugs that may cause them far more harm than good.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Stem cells, including pluripotent stem cells (non-embryonic adult cells that are artificially reprogrammed to mimic embryonic stem cells), are unique in their ability to differentiate into specialized cells, such as heart or muscle or nerve cells. As a result, they provide an important tool for medical research, treatment, and drug development.
For example, stem cells can play a substantial role in the discovery of new medicines that are more effective and safer for patients. They can also be used in the field of regenerative medicine, where various tissues and organs can be generated to replace damaged ones, for application to spinal cord injuries, Parkinson’s disease, diabetes, and perhaps even Alzheimer’s. In addition, given their ability to duplicate the functions of a whole host of other cells, stem cells are becoming important in all types of advanced biomedical research, helping us understand the most basic workings of the human cell and human body.
But one of the lesser known, though potentially huge applications of stem cell technology, involves the early stage testing of drug candidates. The pharmaceutical industry can spend vast amounts of money developing and introducing a new drug, only to find out later that it has negative effects on the heart, liver, or other organs. As a result, the drug must be limited or withdrawn, greatly reducing, or even eliminating, the anticipated profit potential. The numbers involved are telling. It can cost over $1 billion to bring a new drug to market, and it can all be lost if the drug is later found to have toxicity issues, such as causing heart problems. In addition to the time and money spent on developing and marketing, companies can face a long string of associated lawsuits.
In the case of Avandia, an anti-diabetic drug produced by GlaxoSmithKline, concerns that the drug may lead to an increased risk of heart attack, even though not firmly established at the time, still led to a major reduction in sales, and a slew of lawsuits. Given that the drug had been bringing in over $2 billion in annual sales prior to the trouble, it was a significant blow, and gives an idea of how much big pharma might be willing to pay for a workable solution.
It’s a problem for which California based VistaGen Therapeutics believes it has the answer, and it all revolves around stem cells. Using advanced stem cell technology, VistaGen has produced functional human cardiac cells that can be used early on in the drug development process to test for cardiotoxicity. Cardiotoxicity has been a factor in over 30% of drug withdrawals, and addressing it is seen as a major market. The use of real human heart cells in pre-clinical testing offers important advantages over traditional testing methods, such as animal testing.
First of all, it can be performed at the earliest stages of development, reducing the risks of developing the wrong drug. It’s also more accurate, since traditional testing involving animals can fail to detect potential risks in humans. And it’s far easier than the large number of patients and lengthy testing required in human trials. By identifying cardiotoxicity issues early in the process, drug developers can take steps to rescue the drug candidate, developing variants that are both functional and safe. Given that stem cells, including non-embryonic stem cells, can be pointed in many different directions, their potential to transform drug development has no clear limit.
But VistaGen is only now beginning to show up on many investors’ radar screens. Its recent strategic drug rescue-related collaboration agreements with Synterys, a medicinal chemistry and drug discovery services company, and Cato Research Ltd., a leading contract research and development organization, were further indications of the recognition VistaGen has earned for the exciting potential of its stem cell technology-based drug rescue initiatives.
The collaborations are intended to help develop safer drug rescue variants by leveraging VistaGen’s drug rescue initiatives with Synterys’ medicinal chemistry expertise and Cato Research’s drug development and regulatory capabilities. In the case of its key collaboration with Synterys, the idea is to combine VistaGen’s human pluripotent stem cell technology platform, called Human Clinical Trials in a Test TubeTM, with modern medicinal chemistry, to generate new safer variants of once-promising drug candidates discontinued in development due to heart toxicity concerns.
VistaGen sees itself as essentially transforming drug development by bring human biology to the front end of the process, attacking cardiotoxicity issues early in the cost curve, and removing much of the risk and uncertainty typically involved in bringing new drugs to market. Perhaps more importantly, it lessens the chance that patients will be asked to play the role of unsuspecting guinea pig, taking drugs that may cause them far more harm than good.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Access Plans, Inc. (APNC) to be Acquired by Aon Affinity for $70M
Access Plans, a leading membership benefits marketing company with customers in the United States and Canada, today announced it will be acquired by Aon Affinity, a unit of global risk management business, Aon Corporation.
Per the agreement, Aon Affinity will acquire all Access Plans outstanding shares and options to acquire the company’s common stock for cash consideration of approximately $70.1 million, subject to adjustment for various necessary and closing expenses; assuming a net cash amount of $15.0 million, the per share cash consideration is approximately $3.30.
Access Plans is a membership plan provider in the specialty rent-to-own market space. The company bundles a wide range of non-insurance, commonly used products and services, from medical, dental, and pharmacy benefits, to groceries, and hotel rooms. The company sells these plans to consumers primarily in retail and rent-to-own businesses established in more than 10,000 stores in the U.S., Canada and Puerto Rico.
Access Plans CEO and Chairman Danny Wright said the acquisition is the next step in the company’s move toward overall company growth and value.
“At Access Plans, we provide opportunities for people to save money on the things they spend money on every day and offer access to products and services they might otherwise be unable to afford,” Wright stated in the press release. “This sale represents a natural step for us. Becoming a part of the leading risk advisory firm translates into a positive outcome for our shareholders, greater options and value for our clients and increased opportunities for our employees.”
Access Plans’ executive team and administrative staff will remain in their Norman, Oklahoma, and Irving, Texas, locations, and will operate as a business unit of Aon Affinity in Hatboro, Penn.
The deal is expected to close during the second quarter of 2012, and is subject to various closing conditions.
For more information visit www.aon.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Per the agreement, Aon Affinity will acquire all Access Plans outstanding shares and options to acquire the company’s common stock for cash consideration of approximately $70.1 million, subject to adjustment for various necessary and closing expenses; assuming a net cash amount of $15.0 million, the per share cash consideration is approximately $3.30.
Access Plans is a membership plan provider in the specialty rent-to-own market space. The company bundles a wide range of non-insurance, commonly used products and services, from medical, dental, and pharmacy benefits, to groceries, and hotel rooms. The company sells these plans to consumers primarily in retail and rent-to-own businesses established in more than 10,000 stores in the U.S., Canada and Puerto Rico.
Access Plans CEO and Chairman Danny Wright said the acquisition is the next step in the company’s move toward overall company growth and value.
“At Access Plans, we provide opportunities for people to save money on the things they spend money on every day and offer access to products and services they might otherwise be unable to afford,” Wright stated in the press release. “This sale represents a natural step for us. Becoming a part of the leading risk advisory firm translates into a positive outcome for our shareholders, greater options and value for our clients and increased opportunities for our employees.”
Access Plans’ executive team and administrative staff will remain in their Norman, Oklahoma, and Irving, Texas, locations, and will operate as a business unit of Aon Affinity in Hatboro, Penn.
The deal is expected to close during the second quarter of 2012, and is subject to various closing conditions.
For more information visit www.aon.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
GlobalSCAPE, Inc. (GSB) Bundles New Highly-Intuitive Mobile Capability from TappIn Acquisition into Secure File Access Platform
Today, GlobalSCAPE®, well-established provider of a host of secure information exchange platforms and SaaS solutions (which first made a name for itself back in 1996 with the popular CuteFTP® product), implemented a new feature for their proven Enhanced File Transfer (EFT) Server™ platform that allows easy, secure access to business files from any popular smartphone/mobile device.
The Secure Mobile Access™ module, combined with EFT Server, represents a powerful incorporation of technology developed by TappIn™, Inc. and acquired by GSB during the 2011 acquisition of the Seattle-based mobile file sharing innovator.
A solution now exists for businesses/IT departments to easily enable employees to simply use their own mobile device. The implications are obvious and the potential benefits to a business are immediate. Allowing employees to stay connected to the business, accessing and sharing files in a secure environment via their own mobile, is a silver-bullet to problems emerging in the constantly evolving, always-on modern workspace.
Since just December when the acquisition was completed, GSB has managed to successfully integrate the convenient, mobile file access capabilities of TappIn’s technology, with the rock-solid security envelope of the EFT Server. This allows the comprehensive, full-spectrum control for managing user access that administrators have come to love about EFT Server, to be extended rapidly via the initiation of a TappIn account activation by the user. Because the files are not stored in the cloud, there is no upload required before accessing.
Direct access to infrastructure-resident corporate data in a secure environment from any mobile device, in an intuitive, easy to use, and easy to manage interface: this kind of anytime, anywhere connectivity with advanced, yet convenient management functionality is impressive and there is significant buzz building about GSB’s aggressive, pioneering strategy.
CEO of GSB, Jim Morris, hailed the convenience this powerful integration brings forth as a perfect solution for delivering enterprise-grade secure file transfer. The expertise brought to the table by TappIn has been instrumental in developing the kind of advanced, highly-effective mobile access solution the market demands and Morris was keen to emphasize this advantage to customers.
A recent report on smartphone adoption shows that although only 17% of American’s own a smartphone, small business owners’ usage is as high as 49% (Forrester Research). More and more devices are emerging into the category thanks to rapidly changing software/hardware relationships, expanding bandwidth, and secure file access and management solutions like those offered by GSB. As the proliferation of smartphones increases the rate of demand for intuitive, powerful solutions to everyday file access and transfer requirements, the market for precisely such capabilities as today’s announcement heralds will continue to grow.
GSB has over a decade and a half of experience bringing businesses and consumers everything from secure FTP servers and managed hosting services endpoint security to workflow automation. For more information on the San Antonio, Texas-based GlobalSCAPE, Inc. please visit the company’s website at: www.GlobalScape.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The Secure Mobile Access™ module, combined with EFT Server, represents a powerful incorporation of technology developed by TappIn™, Inc. and acquired by GSB during the 2011 acquisition of the Seattle-based mobile file sharing innovator.
A solution now exists for businesses/IT departments to easily enable employees to simply use their own mobile device. The implications are obvious and the potential benefits to a business are immediate. Allowing employees to stay connected to the business, accessing and sharing files in a secure environment via their own mobile, is a silver-bullet to problems emerging in the constantly evolving, always-on modern workspace.
Since just December when the acquisition was completed, GSB has managed to successfully integrate the convenient, mobile file access capabilities of TappIn’s technology, with the rock-solid security envelope of the EFT Server. This allows the comprehensive, full-spectrum control for managing user access that administrators have come to love about EFT Server, to be extended rapidly via the initiation of a TappIn account activation by the user. Because the files are not stored in the cloud, there is no upload required before accessing.
Direct access to infrastructure-resident corporate data in a secure environment from any mobile device, in an intuitive, easy to use, and easy to manage interface: this kind of anytime, anywhere connectivity with advanced, yet convenient management functionality is impressive and there is significant buzz building about GSB’s aggressive, pioneering strategy.
CEO of GSB, Jim Morris, hailed the convenience this powerful integration brings forth as a perfect solution for delivering enterprise-grade secure file transfer. The expertise brought to the table by TappIn has been instrumental in developing the kind of advanced, highly-effective mobile access solution the market demands and Morris was keen to emphasize this advantage to customers.
A recent report on smartphone adoption shows that although only 17% of American’s own a smartphone, small business owners’ usage is as high as 49% (Forrester Research). More and more devices are emerging into the category thanks to rapidly changing software/hardware relationships, expanding bandwidth, and secure file access and management solutions like those offered by GSB. As the proliferation of smartphones increases the rate of demand for intuitive, powerful solutions to everyday file access and transfer requirements, the market for precisely such capabilities as today’s announcement heralds will continue to grow.
GSB has over a decade and a half of experience bringing businesses and consumers everything from secure FTP servers and managed hosting services endpoint security to workflow automation. For more information on the San Antonio, Texas-based GlobalSCAPE, Inc. please visit the company’s website at: www.GlobalScape.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
GBS Enterprises, Inc. (GBSX) Provides Shareholder Update, Q3 and Nine Months Financial Results
GBS Enterprises is a 50 percent parent company of GROUP Business Software AG (GBS), a global software and services company specializing in application modernization and cloud automation. GBS Enterprises today provided a shareholder update and financial results for the three and nine months ended Dec. 31, 2011.
Joerg Ott, CEO of GBS Enterprises, said the company grew year-over-year revenue by 53.5 percent during the 2011 third quarter, reflecting revenue generated through its core software and services business. Despite this growth, Ott said the company is focusing on the “much larger” opportunity with its Transformer technology and Cloud Automation capabilities, which he said will position the company for strong growth going forward.
“Transformer is already demonstrating a significant impact helping companies to gain insight into their business applications and enabling them to formulate and execute a strategy to modernize those applications,” Ott stated in the press release. “We have already completed pilot projects with large financial services organizations in New York and are in the process of beginning large engagements with these and other enterprise level customers both in North America and Europe. The demand and need for our technology and application expertise is significant and going forward we anticipate a rapid expansion of our business pipeline.”
The company highlighted several other 2011 business updates, including its acquisition of IDC Global, GroupWare and Pavone AG, and announced third quarter and nine months financial results.
GBS Enterprises reported revenue for the third quarter ended Dec. 31, 2011, at approximately $8.2 million, an increase of 53.5 percent as compared to approximately $5.4 million for the same period the year prior. Revenue for the nine-month period ended Dec. 31, 2011, totaled approximately $21.3 million, an increase of approximately 18.7 percent, as compared to approximately $18 million for the same period the year prior.
Gross profit for the quarter ended Dec. 31, 2011, totaled approximately $3.5 million, a 33.8 percent increase compared to approximately $2.6 million for the same period the year prior. Gross profit margin during the 2011 period was approximately 43 percent as compared to approximately 49.3 percent for the 2010 period. Gross profit for the nine months ended Dec. 31, 2011, totaled approximately $10.5 million, an increase of approximately 13 percent, as compared to approximately $9.3 million for the first nine months of 2010. Gross profit margin for the 2011 nine-month period was approximately 49.1 percent as compared to approximately 51.6 percent the prior year.
The company was cash flow positive from operations through the first nine months of 2011. During the quarter ended Dec. 31, 2011, certain warrant holders exercised their warrants to purchase an aggregate of 2,020,000 shares of common stock for a total purchase price of $3,030,000 before fees.
As of Dec. 31, 2011, GBS Enterprises had approximately $3.5 million in cash and cash equivalents; and total current assets and total assets at approximately $10.2 million and approximately $86.7 million, respectively.
For more information visit www.gbsx.us
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Joerg Ott, CEO of GBS Enterprises, said the company grew year-over-year revenue by 53.5 percent during the 2011 third quarter, reflecting revenue generated through its core software and services business. Despite this growth, Ott said the company is focusing on the “much larger” opportunity with its Transformer technology and Cloud Automation capabilities, which he said will position the company for strong growth going forward.
“Transformer is already demonstrating a significant impact helping companies to gain insight into their business applications and enabling them to formulate and execute a strategy to modernize those applications,” Ott stated in the press release. “We have already completed pilot projects with large financial services organizations in New York and are in the process of beginning large engagements with these and other enterprise level customers both in North America and Europe. The demand and need for our technology and application expertise is significant and going forward we anticipate a rapid expansion of our business pipeline.”
The company highlighted several other 2011 business updates, including its acquisition of IDC Global, GroupWare and Pavone AG, and announced third quarter and nine months financial results.
GBS Enterprises reported revenue for the third quarter ended Dec. 31, 2011, at approximately $8.2 million, an increase of 53.5 percent as compared to approximately $5.4 million for the same period the year prior. Revenue for the nine-month period ended Dec. 31, 2011, totaled approximately $21.3 million, an increase of approximately 18.7 percent, as compared to approximately $18 million for the same period the year prior.
Gross profit for the quarter ended Dec. 31, 2011, totaled approximately $3.5 million, a 33.8 percent increase compared to approximately $2.6 million for the same period the year prior. Gross profit margin during the 2011 period was approximately 43 percent as compared to approximately 49.3 percent for the 2010 period. Gross profit for the nine months ended Dec. 31, 2011, totaled approximately $10.5 million, an increase of approximately 13 percent, as compared to approximately $9.3 million for the first nine months of 2010. Gross profit margin for the 2011 nine-month period was approximately 49.1 percent as compared to approximately 51.6 percent the prior year.
The company was cash flow positive from operations through the first nine months of 2011. During the quarter ended Dec. 31, 2011, certain warrant holders exercised their warrants to purchase an aggregate of 2,020,000 shares of common stock for a total purchase price of $3,030,000 before fees.
As of Dec. 31, 2011, GBS Enterprises had approximately $3.5 million in cash and cash equivalents; and total current assets and total assets at approximately $10.2 million and approximately $86.7 million, respectively.
For more information visit www.gbsx.us
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The FluoroPharma Medical, Inc. (FPMI) Edge
The positive report just released by Zacks Small-Cap Research on FluoroPharma Medical, developer of advanced medical diagnostic imaging tracer products for use with positron emission tomography (PET), highlights the principal advantages of FluoroPharma in the healthcare market. Although healthcare itself is a steadily rising sea, with aging baby boomers continuing to feed the market, the distinctive advantages of FluoroPharma give the company a unique edge.
FluoroPharma is developing specialized tracer chemicals that are able to integrate themselves into subtle bodily processes, allowing sophisticated PET technology to detect biological events at the cellular and molecular level, long before the manifestation of disease symptoms. As such, PET technology represents an internal detection resolution unmatched by other diagnostic imaging approaches, and FluoroPharma’s focus on PET provides the company’s first key advantage in the healthcare marketplace.
In addition, FluoroPharma’s main radiopharmaceutical products target the extensive coronary artery disease (CAD) market. CAD remains a major global killer and is the subject of massive funding for the development of associated products. FluoroPharma has three tracer products directly related to CAD. CardioPET helps identify patients that will benefit from PCI or revascularization and guide intervention, and can evaluate CAD in patients that cannot go through stress tests. BFPET can be used for the detection of presumptive CAD in combination with stress testing, as well as for the improved detection of CAD related to multi-vessel disease. VasoPET can be used for evaluating patients experiencing Acute Coronary Syndrome or a risk of stroke, or for evaluating therapy following an acute cardiac event or stroke.
Yet another advantage for FluoroPharma is the unmatched capabilities of their particular tracers. Current CAD related PET tracers carry an unusually high cost, and have also experienced safety issues and availability shortages. As a result, there is a significant demand for new approaches, as offered by FluoroPharma.
For more information, see the company website at www.FluoroPharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
FluoroPharma is developing specialized tracer chemicals that are able to integrate themselves into subtle bodily processes, allowing sophisticated PET technology to detect biological events at the cellular and molecular level, long before the manifestation of disease symptoms. As such, PET technology represents an internal detection resolution unmatched by other diagnostic imaging approaches, and FluoroPharma’s focus on PET provides the company’s first key advantage in the healthcare marketplace.
In addition, FluoroPharma’s main radiopharmaceutical products target the extensive coronary artery disease (CAD) market. CAD remains a major global killer and is the subject of massive funding for the development of associated products. FluoroPharma has three tracer products directly related to CAD. CardioPET helps identify patients that will benefit from PCI or revascularization and guide intervention, and can evaluate CAD in patients that cannot go through stress tests. BFPET can be used for the detection of presumptive CAD in combination with stress testing, as well as for the improved detection of CAD related to multi-vessel disease. VasoPET can be used for evaluating patients experiencing Acute Coronary Syndrome or a risk of stroke, or for evaluating therapy following an acute cardiac event or stroke.
Yet another advantage for FluoroPharma is the unmatched capabilities of their particular tracers. Current CAD related PET tracers carry an unusually high cost, and have also experienced safety issues and availability shortages. As a result, there is a significant demand for new approaches, as offered by FluoroPharma.
For more information, see the company website at www.FluoroPharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Friday, February 24, 2012
North American Palladium Ltd. (PAL) Appoints Peck as Head of Exploration
North American Palladium Ltd., an established precious metals producer, has announced that Dr. David C. Peck has been appointed as the company’s head of exploration. Dr. Peck will begin his new position on March 1.
Peck is a professional geoscientist and has almost 30 years of experience in exploration, as well as extensive research experience focused on magmatic Ni-Cu-PGE (nickel, copper, platinum group of elements) ore deposits. Peck is recognized as a worldwide expert in PGE exploration and has served as a senior technical and strategic consultant for many public and private companies; he has also worked on exploration and mining projects in more than a dozen countries. Peck was additionally involved in several noteworthy magmatic Ni-Cu-PGE discoveries in Canada and also overseas.
Dr. Peck most recently served as the president and senior technical and strategic consultant at Revelation Geoscience, a geoscience and exploration consulting company that he helped found. He has also served as the global nickel commodity leader at Anglo American plc, overseeing both the technical and strategic aspects of its global nickel exploration programs, and as a senior geologist for Falconbridge Ltd., overseeing project generation in western North America. Dr. Peck has additionally worked as a senior mineral deposits geologist for the Manitoba Geological Survey, as an adjunct professor at two Canada universities, as a graduate course instructor in mineral exploration at Laurentian University, and as the technical lead for a multi-year mineral potential study sponsored by the Ontario Geological Survey. Dr. Peck has authored many public presentations and government and academic publications relating to his specialization area.
North American Palladium anticipates that Peck’s expertise will significantly enhance the company’s efforts to achieve its organic growth initiatives, as the company has merely begun to scratch the surface of delineating future increases to its palladium resources at the company’s Lac des Iles (LDI) mine and adjacent properties. Worldwide, few available palladium exploration opportunities are as technically attractive and have such a low risk profile as LDI. The company’s current project pipeline promises great potential for continued resource expansions and new discoveries.
North American Palladium has been operating LDI – its flagship mine – in Ontario, Canada, since 1993. One of only two primary producers of palladium on earth, LDS is presently undergoing a large expansion to increase production and lessen cash costs per ounce. The company additionally operates the Vezza gold mine, which is located in the Abitibi region of Quebec.
For further information about North American Palladium, visit www.nap.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Peck is a professional geoscientist and has almost 30 years of experience in exploration, as well as extensive research experience focused on magmatic Ni-Cu-PGE (nickel, copper, platinum group of elements) ore deposits. Peck is recognized as a worldwide expert in PGE exploration and has served as a senior technical and strategic consultant for many public and private companies; he has also worked on exploration and mining projects in more than a dozen countries. Peck was additionally involved in several noteworthy magmatic Ni-Cu-PGE discoveries in Canada and also overseas.
Dr. Peck most recently served as the president and senior technical and strategic consultant at Revelation Geoscience, a geoscience and exploration consulting company that he helped found. He has also served as the global nickel commodity leader at Anglo American plc, overseeing both the technical and strategic aspects of its global nickel exploration programs, and as a senior geologist for Falconbridge Ltd., overseeing project generation in western North America. Dr. Peck has additionally worked as a senior mineral deposits geologist for the Manitoba Geological Survey, as an adjunct professor at two Canada universities, as a graduate course instructor in mineral exploration at Laurentian University, and as the technical lead for a multi-year mineral potential study sponsored by the Ontario Geological Survey. Dr. Peck has authored many public presentations and government and academic publications relating to his specialization area.
North American Palladium anticipates that Peck’s expertise will significantly enhance the company’s efforts to achieve its organic growth initiatives, as the company has merely begun to scratch the surface of delineating future increases to its palladium resources at the company’s Lac des Iles (LDI) mine and adjacent properties. Worldwide, few available palladium exploration opportunities are as technically attractive and have such a low risk profile as LDI. The company’s current project pipeline promises great potential for continued resource expansions and new discoveries.
North American Palladium has been operating LDI – its flagship mine – in Ontario, Canada, since 1993. One of only two primary producers of palladium on earth, LDS is presently undergoing a large expansion to increase production and lessen cash costs per ounce. The company additionally operates the Vezza gold mine, which is located in the Abitibi region of Quebec.
For further information about North American Palladium, visit www.nap.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Access Pharmaceuticals, Inc. (ACCP) Partner Receives China Regulatory and Marketing Approval for MuGard
Access Pharmaceuticals Inc., a biopharm company focused on the development of treatments in the areas of oncology, diabetes, and RNAi, today announced that its MuGard partner in China, Rhei Pharmaceuticals HK Ltd., has received regulatory approval from the State Food and Drug Administration (SFDA) to market MuGard in China.
China’s regulatory agency approved MuGard to treat cancer patients afflicted with oral mucositis a debilitating side effect of many anticancer treatments. The approval provides Access the opportunity to tap into an expansive market with a largely unmet medical need. Access will soon begin manufacturing MuGard in the United States to meet demand created by Jian An Ltd., Rhei’s sales and marketing partner in China.
“Receiving final marketing approval from the SFDA of China is a transformative milestone for our global MuGard program. China represents a key target market with its large and increasingly affluent population and its desire for improved oncology care,” Jeffrey B. Davis, president and CEO of Access stated in the press release. “With the approval process now complete, we look forward to moving as quickly as we can to complete manufacturing so Rhei and Jian An can launch MuGard through their well-established sales and marketing infrastructure in China.”
“China is one of the fastest growing oncology markets and cancer supportive care has been improving throughout recent years,” said Sven De Backer, CEO of Rhei. “Rhei and Jian An are proud to bring MuGard to patients and physicians as we believe it is a critical and valuable product that addresses a significant unmet need for a large and growing patient population.”
Access and Rhei last year signed a supply agreement for MuGard, which ensured manufacturing capacity of up to a minimum of $30 million of product in the licensed territories. Access also approved a sub-license agreement between Rhei and Jian designed to leverage Jian An’s sales, marketing, and regulatory infrastructure for the launch of MuGard in China and Taiwan.
For more information visit www.accesspharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
China’s regulatory agency approved MuGard to treat cancer patients afflicted with oral mucositis a debilitating side effect of many anticancer treatments. The approval provides Access the opportunity to tap into an expansive market with a largely unmet medical need. Access will soon begin manufacturing MuGard in the United States to meet demand created by Jian An Ltd., Rhei’s sales and marketing partner in China.
“Receiving final marketing approval from the SFDA of China is a transformative milestone for our global MuGard program. China represents a key target market with its large and increasingly affluent population and its desire for improved oncology care,” Jeffrey B. Davis, president and CEO of Access stated in the press release. “With the approval process now complete, we look forward to moving as quickly as we can to complete manufacturing so Rhei and Jian An can launch MuGard through their well-established sales and marketing infrastructure in China.”
“China is one of the fastest growing oncology markets and cancer supportive care has been improving throughout recent years,” said Sven De Backer, CEO of Rhei. “Rhei and Jian An are proud to bring MuGard to patients and physicians as we believe it is a critical and valuable product that addresses a significant unmet need for a large and growing patient population.”
Access and Rhei last year signed a supply agreement for MuGard, which ensured manufacturing capacity of up to a minimum of $30 million of product in the licensed territories. Access also approved a sub-license agreement between Rhei and Jian designed to leverage Jian An’s sales, marketing, and regulatory infrastructure for the launch of MuGard in China and Taiwan.
For more information visit www.accesspharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Charles & Covard Ltd. (CTHR) Announce Fourth Quarter 2011 Results Charles & Covard Ltd. (CTHR) Announce Fourth Quarter 2011 Results
Charles & Covard Ltd. is the sole global source of moissanite. This is a unique, nearly colorless created gemstone that is distinct from other gemstones and jewels based on its fire, brilliance, luster, durability, and rarity. This gemstone is incorporated into fine jewelry and sold throughout the world.
The company announced yesterday its financial results for the fourth quarter and full year of 2011, ended December 31. It reported that net sales more than doubled while net income quadrupled in the fourth quarter.
Net sales increased 105% to $7.2 million versus $3.5 million in the same period last year. Loose moissanite gemstone sales increased 149% to $4.8 million versus just $1.9 million last year. Finished jewelry sales rose 50% to $2.4 million versus $1.6 million last year. For the full year, net sales rose by 26% to $16 million versus $12.7 million in 2010. 2011 saw sales of loose moissanite gemstones climb 19% to $12.1 million and sales of moissanite jewelry climb by 57% to $4 million.
Charles & Covard also enjoyed increasing profits. Its net income in the fourth quarter rose to $1.8 million, or 9 cents a share, compared to $410,000, or 2 cents a share, in the year ago period. Net income for the full year was flat versus 2010 at $1.6 million, or 8 cents a share. Notably, the company experienced positive cash flow for the entire year of $3.5 million.
The company, especially in the fourth quarter, benefited from its investments in new sales and marketing initiatives throughout its distribution channels. The company’s sales from its television shopping network customers were particularly strong. The company also expanded its sales efforts overseas, including into emerging markets such as China.
For more information about Charles & Covard and moissanite, please visit the company’s website at www.charlesandcovard.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The company announced yesterday its financial results for the fourth quarter and full year of 2011, ended December 31. It reported that net sales more than doubled while net income quadrupled in the fourth quarter.
Net sales increased 105% to $7.2 million versus $3.5 million in the same period last year. Loose moissanite gemstone sales increased 149% to $4.8 million versus just $1.9 million last year. Finished jewelry sales rose 50% to $2.4 million versus $1.6 million last year. For the full year, net sales rose by 26% to $16 million versus $12.7 million in 2010. 2011 saw sales of loose moissanite gemstones climb 19% to $12.1 million and sales of moissanite jewelry climb by 57% to $4 million.
Charles & Covard also enjoyed increasing profits. Its net income in the fourth quarter rose to $1.8 million, or 9 cents a share, compared to $410,000, or 2 cents a share, in the year ago period. Net income for the full year was flat versus 2010 at $1.6 million, or 8 cents a share. Notably, the company experienced positive cash flow for the entire year of $3.5 million.
The company, especially in the fourth quarter, benefited from its investments in new sales and marketing initiatives throughout its distribution channels. The company’s sales from its television shopping network customers were particularly strong. The company also expanded its sales efforts overseas, including into emerging markets such as China.
For more information about Charles & Covard and moissanite, please visit the company’s website at www.charlesandcovard.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
First Titan Corp. (FTTN) CEO to Meet with Intrepid Drilling Regarding Partnership
First Titan Corp. CEO, Robert Federowicz, will be meeting with executives from Intrepid Drilling, LLC to review preparations for spudding the partnership’s new oil and gas well at the South Lake Charles Prospect in Calcasieu, La. The meetings are scheduled to take place this week.
At the meeting, Intrepid Drilling will go over drilling plans with Federowicz, including final details. Intrepid Manager William E. Simmons will be on hand to present the project timeline to Federowicz. The company signed an agreement last month that places Intrepid Drilling in charge of drilling and operating the new well. The well’s spud date is currently set for March 1.
An emerging energy company, First Titan will rely heavily on its partner’s drilling and production experience to help make the South Lake Charles Prospect a success. Plans call for the company to drill to a total depth of 15,300 ft. at the project location. The project’s total maximum potential for all categories exceeds 60 billion cubic feet of gas and four million barrels of oil.
For more information on FTTN’s drilling initiative, please visit the company’s website at www.firsttitanenergy.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
At the meeting, Intrepid Drilling will go over drilling plans with Federowicz, including final details. Intrepid Manager William E. Simmons will be on hand to present the project timeline to Federowicz. The company signed an agreement last month that places Intrepid Drilling in charge of drilling and operating the new well. The well’s spud date is currently set for March 1.
An emerging energy company, First Titan will rely heavily on its partner’s drilling and production experience to help make the South Lake Charles Prospect a success. Plans call for the company to drill to a total depth of 15,300 ft. at the project location. The project’s total maximum potential for all categories exceeds 60 billion cubic feet of gas and four million barrels of oil.
For more information on FTTN’s drilling initiative, please visit the company’s website at www.firsttitanenergy.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Thursday, February 23, 2012
MELA Sciences, Inc. (MELA) Device Shown to Improve Melanoma Detection
MelaFind, a non-invasive, multispectral computer vision system developed by MELA Sciences, has been shown to improve melanoma detection in a recent study. The study, involving 179 dermatologists, was published online on Feb. 20 in the Archives of Dermatology.
Before obtaining the MelaFind output, the average sensitivity – or ability to detect disease – of the dermatologists in the study was 69 percent; after obtaining the MelaFind output, the dermatologists’ average sensitivity increased to 94 percent. The percentage of dermatologists detecting all of the present melanomas during the study rose from 13 percent to 70 percent with the aid of MelaFind. Specificity, or the ability to correctly rule out disease when it isn’t present, also increased on MelaFind negative lesions during the study, resulting in a 17 percent reduction of biopsies of the histologically benign lesions.
MelaFind recently received approval from the FDA. The device uses light from visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm beneath the skin’s surface. MelaFind analyzes the three-dimensional morphologic disorganization under the surface of the legion, providing an easy-to-interpret and unambiguous output that dermatologists can incorporate into their biopsy decision-making processes.
MELA Sciences is performing a controlled launch of MelaFind in the northeastern U.S. and in several key cities in Germany. MELA Sciences will work with the participating dermatology practices to train and assist them as they incorporate MelaFind. This approach will serve as the basis for a more widespread distribution of MelaFind in the future.
MELA Sciences is a medical device company that focuses on the design, development, and commercialization of non-invasive dermatological tools to aid in the detection of melanoma. MelaFind is the company’s flagship product. In addition to its FDA approval for use in the United States, MelaFind has also received the CE Mark and has been approved for use in the European Union.
For further information about the company, visit www.melasciences.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Before obtaining the MelaFind output, the average sensitivity – or ability to detect disease – of the dermatologists in the study was 69 percent; after obtaining the MelaFind output, the dermatologists’ average sensitivity increased to 94 percent. The percentage of dermatologists detecting all of the present melanomas during the study rose from 13 percent to 70 percent with the aid of MelaFind. Specificity, or the ability to correctly rule out disease when it isn’t present, also increased on MelaFind negative lesions during the study, resulting in a 17 percent reduction of biopsies of the histologically benign lesions.
MelaFind recently received approval from the FDA. The device uses light from visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm beneath the skin’s surface. MelaFind analyzes the three-dimensional morphologic disorganization under the surface of the legion, providing an easy-to-interpret and unambiguous output that dermatologists can incorporate into their biopsy decision-making processes.
MELA Sciences is performing a controlled launch of MelaFind in the northeastern U.S. and in several key cities in Germany. MELA Sciences will work with the participating dermatology practices to train and assist them as they incorporate MelaFind. This approach will serve as the basis for a more widespread distribution of MelaFind in the future.
MELA Sciences is a medical device company that focuses on the design, development, and commercialization of non-invasive dermatological tools to aid in the detection of melanoma. MelaFind is the company’s flagship product. In addition to its FDA approval for use in the United States, MelaFind has also received the CE Mark and has been approved for use in the European Union.
For further information about the company, visit www.melasciences.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Synergy Resources Corp. (SYRG) Strengthens DJ Basin Position, Enters Agreement to Acquire 8,700 Acres in Colorado
Today, Synergy Resources announced further strengthening of the company’s Denver-Julesburg Basin (Colorado, Kansas, Nebraska, Wyoming) position via entry into an agreement with DeClar Oil & Gas, Inc. and Wolf Point Exploration, LLC covering certain mineral lease interests on some 8,700 undeveloped acres in the DJ Basin.
This is a solid move for SYRG that comes directly after the horizontal Niobrara well participation announcement involving PDC Energy (announced Feb. 21, SYRG owns a 28.75% WI). Synergy Resources has developed an impressive core area of operations in the DJ Basin focusing on the 7th largest domestic oil and gas field, the resource rich Wattenberg (by proved gas reserves, 9th in terms of production).
The acreage covered by today’s agreement falls in Colorado’s Larimer, Morgan and Weld counties, bringing SYRG up to a total of approximately 22.5k acres in the three counties. As per terms of the agreement, SYRG will be required to drill at least two wells in two years on the acreage and closing of the transaction is projected to be March 15 of this year (subject to customary closing conditions including due diligence or adjustments).
President of SYRG, Ed Holloway, detailed the exciting portfolio of leases assembled by DeClar and Wolf Point a little, explaining that well control and take-away capacity parameters for the properties all fell within company guidelines. Holloway indicated that these properties have production potential from multiple pay zones, including targets in the Niobrara, Greenhorn, J-Sand, and D-Sand formations.
Citing the overall organic growth of the company and its position in the DJ Basin, Holloway argued that the agreement strengthens SYRG’s position in what is the heart of an emerging horizontal play in the three-county area. Holloway explained that this agreement offers a great blend of both vertical and horizontal drilling opportunities for the company and pledged to implement the same practices which have been used so far to ensure maximized shareholder value from operations.
Pledging to continue explorative and acquisitive efforts in the DJ Basin on a case-by-case basis as opportunity dictates, Holloway concluded by reaffirming the cost and production strategy which has made SYRG successful.
This is as gas prices continue climbing steadily higher amid clear indicators of a destabilizing global supply chain, fueled in large part by Middle East tensions and outstanding sovereign debt concerns, especially in EU nations. It paints a bright picture for domestic energy production outlooks, as investors all around the world turn towards a rapidly re-emerging North American hydrocarbon boom.
For more information on the agreement, or to stay up to date on the latest developments at Synergy Resources Corp., please visit the company’s website at www.SynergyResourcesCorporation.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
This is a solid move for SYRG that comes directly after the horizontal Niobrara well participation announcement involving PDC Energy (announced Feb. 21, SYRG owns a 28.75% WI). Synergy Resources has developed an impressive core area of operations in the DJ Basin focusing on the 7th largest domestic oil and gas field, the resource rich Wattenberg (by proved gas reserves, 9th in terms of production).
The acreage covered by today’s agreement falls in Colorado’s Larimer, Morgan and Weld counties, bringing SYRG up to a total of approximately 22.5k acres in the three counties. As per terms of the agreement, SYRG will be required to drill at least two wells in two years on the acreage and closing of the transaction is projected to be March 15 of this year (subject to customary closing conditions including due diligence or adjustments).
President of SYRG, Ed Holloway, detailed the exciting portfolio of leases assembled by DeClar and Wolf Point a little, explaining that well control and take-away capacity parameters for the properties all fell within company guidelines. Holloway indicated that these properties have production potential from multiple pay zones, including targets in the Niobrara, Greenhorn, J-Sand, and D-Sand formations.
Citing the overall organic growth of the company and its position in the DJ Basin, Holloway argued that the agreement strengthens SYRG’s position in what is the heart of an emerging horizontal play in the three-county area. Holloway explained that this agreement offers a great blend of both vertical and horizontal drilling opportunities for the company and pledged to implement the same practices which have been used so far to ensure maximized shareholder value from operations.
Pledging to continue explorative and acquisitive efforts in the DJ Basin on a case-by-case basis as opportunity dictates, Holloway concluded by reaffirming the cost and production strategy which has made SYRG successful.
This is as gas prices continue climbing steadily higher amid clear indicators of a destabilizing global supply chain, fueled in large part by Middle East tensions and outstanding sovereign debt concerns, especially in EU nations. It paints a bright picture for domestic energy production outlooks, as investors all around the world turn towards a rapidly re-emerging North American hydrocarbon boom.
For more information on the agreement, or to stay up to date on the latest developments at Synergy Resources Corp., please visit the company’s website at www.SynergyResourcesCorporation.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
SecureAlert, Inc. (SCRA) Reports Record Monitoring Revenues for Fiscal Q1
SecureAlert Inc., an international provider of offender monitoring and electronic tracking solutions used by law enforcement agencies worldwide, today announced record monitoring revenue results for the first fiscal quarter.
“Monitoring revenues continue to show strength at record levels, which are a key indicator of the overall health and progress of SecureAlert,” John L. Hastings, III, CEO of SecureAlert stated in the press release. “Importantly, we are evermore committed to achieving sustainable profitability, while leveraging our core competencies in the rapidly expanding global markets.”
For the first fiscal quarter ended Dec. 31, 2011, SecureAlert reported revenues of $5.5 million, a 51 percent increase compared to revenues of $3.6 million reported for the comparable three months of 2010.
Of these revenues, $4.2 million and $3.4 million were derived from monitoring services for the three months ended Dec. 31, 2011, and 2010, respectively, representing a 25 percent increase.
Fiscal first quarter 2011 product revenues increased 393 percent to $1.2 million compared to $256,614 reported for the three months ended Dec. 31, 2010.
Gross profit margins for the three months ended Dec. 31, 2011, and 2010 remained flat at 49 percent of revenues for both reported periods.
SecureAlert reported a net loss of $1.6 million, a 22 percent increase compared to $2.0 million for the three months ended Dec. 31, 2010.
For more information visit www.securealert.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“Monitoring revenues continue to show strength at record levels, which are a key indicator of the overall health and progress of SecureAlert,” John L. Hastings, III, CEO of SecureAlert stated in the press release. “Importantly, we are evermore committed to achieving sustainable profitability, while leveraging our core competencies in the rapidly expanding global markets.”
For the first fiscal quarter ended Dec. 31, 2011, SecureAlert reported revenues of $5.5 million, a 51 percent increase compared to revenues of $3.6 million reported for the comparable three months of 2010.
Of these revenues, $4.2 million and $3.4 million were derived from monitoring services for the three months ended Dec. 31, 2011, and 2010, respectively, representing a 25 percent increase.
Fiscal first quarter 2011 product revenues increased 393 percent to $1.2 million compared to $256,614 reported for the three months ended Dec. 31, 2010.
Gross profit margins for the three months ended Dec. 31, 2011, and 2010 remained flat at 49 percent of revenues for both reported periods.
SecureAlert reported a net loss of $1.6 million, a 22 percent increase compared to $2.0 million for the three months ended Dec. 31, 2010.
For more information visit www.securealert.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Oragenics, Inc. (ORNI) Clinical Trial Demonstrates Dental Health Benefits of EvorKids® in Cavity-prone Children
Oragenics, a nutraceutical company focused on oral care probiotics for humans and companion pets, today announced the completion of an independently conducted clinical trial for EvorKids®, the company’s branded product designed to support oral health in children ages 3 to 11.
The randomized, double-blind study enrolled 60 six- to 12-year old children prone to tooth decay/cavity (caries). The study evaluated baseline levels of key oral bacterial species mutans Streptococci and Lactobacilli, which are recognized as risk factors to the development of caries. After four weeks of treatment of EvorKids®, Oragenis reports that results show a statistically significant decrease from baseline of the levels with no adverse events reported during the trial.
Mark Cannon, DDS, the lead author of this independent study, is a faculty member at Northwestern University, an attending physician at Children’s Memorial Hospital, Chicago, and a diplomate of the American Board of Pediatric Dentistry. Dr. Cannon said the clinical study demonstrates that caries-prone children may benefit from the use of probiotics as part of a daily dental hygiene regimen.
John N. Bonfiglio, Ph.D., CEO of Oragenics, noted the results impact on the company itself.
“Oragenics is encouraged by the results of this first independent study in children employing the company’s proprietary blend of oral care probiotics,” Dr. Bonfiglio stated in the press release. “These data agree with previous results obtained from animal and adult human studies conducted by both Oragenics and independent investigators such as Dr. Cannon, and reinforce the claim that the active ingredient in EvoraKids, ProBiora3®, promotes oral health by helping to maintain a naturally balanced oral microflora.”
Oragenics said the trial details and results will be presented on March 21, 2012, at the American Association for Dental Research (AADR) Annual Meeting in Tampa, Fla. The study is titled “DNA-PCR and CRT Results in Children after Probiotic Use,” as part of an entire scientific session of clinical studies related to dental cariology.
For more information visit www.iadr.org
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The randomized, double-blind study enrolled 60 six- to 12-year old children prone to tooth decay/cavity (caries). The study evaluated baseline levels of key oral bacterial species mutans Streptococci and Lactobacilli, which are recognized as risk factors to the development of caries. After four weeks of treatment of EvorKids®, Oragenis reports that results show a statistically significant decrease from baseline of the levels with no adverse events reported during the trial.
Mark Cannon, DDS, the lead author of this independent study, is a faculty member at Northwestern University, an attending physician at Children’s Memorial Hospital, Chicago, and a diplomate of the American Board of Pediatric Dentistry. Dr. Cannon said the clinical study demonstrates that caries-prone children may benefit from the use of probiotics as part of a daily dental hygiene regimen.
John N. Bonfiglio, Ph.D., CEO of Oragenics, noted the results impact on the company itself.
“Oragenics is encouraged by the results of this first independent study in children employing the company’s proprietary blend of oral care probiotics,” Dr. Bonfiglio stated in the press release. “These data agree with previous results obtained from animal and adult human studies conducted by both Oragenics and independent investigators such as Dr. Cannon, and reinforce the claim that the active ingredient in EvoraKids, ProBiora3®, promotes oral health by helping to maintain a naturally balanced oral microflora.”
Oragenics said the trial details and results will be presented on March 21, 2012, at the American Association for Dental Research (AADR) Annual Meeting in Tampa, Fla. The study is titled “DNA-PCR and CRT Results in Children after Probiotic Use,” as part of an entire scientific session of clinical studies related to dental cariology.
For more information visit www.iadr.org
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Vringo, Inc. (VRNG) Receives Notice of Allowance from EPO for Its First International Patent
Vringo, Inc. (VRNG) Receives Notice of Allowance from EPO for Its First International Patent
Vringo, a software platform provider for social and video mobile applications, announced today that the European Patent Office (EPO) has sent a notice of allowance to the company for its first international patent covering aspects of Vringo’s video and mobile personalization technologies. The company anticipates that this patent will further protect Vringo’s video ringtone intellectual property and other applications for personalizing customers’ mobile experience.
The company’s notice of allowance from the EPO relates to the expansion of “Personalization Content Sharing System and Method,” which is patent number 8,041,401 issued by the United States Patent and Trademark Office. When granted by the EPO, this patent will have potential jurisdiction in approximately 39 countries in the EU. Vringo anticipates the patent will provide the company with a competitive edge as it continues to increase its core mobile video technology worldwide.
About six years ago, before most of the world was aware of the huge market potential of mobile applications, Vringo had already developed its core intellectual property and began filing initial patent applications. Since the company was founded, Vringo has filed more than 20 patent applications in the United States and worldwide.
Vringo’s three patents previously issued in the U.S. cover the core features of the company’s video ringtone sharing capabilities, as well as the personalization of standard compiled and signed software application downloads. Vringo anticipates that the EPO will issue this latest patent within the next six months, after which time the patent won’t expire before January 2027.
Vringo’s award-winning ringtone application and other mobile software platforms – including Facetones, Video Remix, and Fan Loyalty – turn the act of making and receiving mobile phone calls into a social experience that is also highly visual. The company’s video ringtone service allows users to create or take video, images, and slideshows from essentially anywhere and transform them into a personalized video call signature. Vringo has introduced its patented VringForward technology – a first for the mobile industry – which enables users to share video clips with others through a simple call. The company’s Facetones application generates an automated video slideshow using photos from friends’ social media Web sites, and this slideshow is played each time the user communicates with a friend through a mobile device.
Vringo’s Video ReMix application partners with music artists and brands, allowing users to create their own music videos by simply tapping on a smartphone or tablet. Finally, the company’s Fan Loyalty platform allows users to interact, vote, and communicate with contestants on reality TV shows that the company has partnered with, as well as downloading clips from these shows and setting them as video ringtones.
For further information about the company, visit www.vringo.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Vringo, a software platform provider for social and video mobile applications, announced today that the European Patent Office (EPO) has sent a notice of allowance to the company for its first international patent covering aspects of Vringo’s video and mobile personalization technologies. The company anticipates that this patent will further protect Vringo’s video ringtone intellectual property and other applications for personalizing customers’ mobile experience.
The company’s notice of allowance from the EPO relates to the expansion of “Personalization Content Sharing System and Method,” which is patent number 8,041,401 issued by the United States Patent and Trademark Office. When granted by the EPO, this patent will have potential jurisdiction in approximately 39 countries in the EU. Vringo anticipates the patent will provide the company with a competitive edge as it continues to increase its core mobile video technology worldwide.
About six years ago, before most of the world was aware of the huge market potential of mobile applications, Vringo had already developed its core intellectual property and began filing initial patent applications. Since the company was founded, Vringo has filed more than 20 patent applications in the United States and worldwide.
Vringo’s three patents previously issued in the U.S. cover the core features of the company’s video ringtone sharing capabilities, as well as the personalization of standard compiled and signed software application downloads. Vringo anticipates that the EPO will issue this latest patent within the next six months, after which time the patent won’t expire before January 2027.
Vringo’s award-winning ringtone application and other mobile software platforms – including Facetones, Video Remix, and Fan Loyalty – turn the act of making and receiving mobile phone calls into a social experience that is also highly visual. The company’s video ringtone service allows users to create or take video, images, and slideshows from essentially anywhere and transform them into a personalized video call signature. Vringo has introduced its patented VringForward technology – a first for the mobile industry – which enables users to share video clips with others through a simple call. The company’s Facetones application generates an automated video slideshow using photos from friends’ social media Web sites, and this slideshow is played each time the user communicates with a friend through a mobile device.
Vringo’s Video ReMix application partners with music artists and brands, allowing users to create their own music videos by simply tapping on a smartphone or tablet. Finally, the company’s Fan Loyalty platform allows users to interact, vote, and communicate with contestants on reality TV shows that the company has partnered with, as well as downloading clips from these shows and setting them as video ringtones.
For further information about the company, visit www.vringo.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Wednesday, February 22, 2012
Repligen Corp. (RGEN) Obtains FDA Grant of Priority Review
Yesterday, Repligen Corp. announced that the U.S. FDA has accepted for filing and granted Priority Review to the company’s new drug application (NDA) for their product SecreFlo. The drug will be used to detect pancreatic duct abnormalities in patients with pancreatitis.
Based in Waltham, MA, Repligen is primarily focused on supplying products that aid in the manufacture of biologic drugs, and is using the accumulated expertise in this field to bring their SecreFlow product to market. The company also has two central nervous system rare disease programs in Phase 1 clinical trials. SecreFlow is a synthetic version of the naturally occurring human hormone secretin, produced in the small intestine and necessary during the human digestive process. SecreFlow can be used in patients to improve MRI quality when examining the pancreas.
SecreFlow is being developed as an alternative method of examining the pancreas, as opposed to endoscopic retrograde cholangiopancreatography (ERCP), an invasive procedure that has documented mortality risks. By granting SecreFlow priority review, the FDA will reduce the time it takes to deliver a decision on marketing approval from ten months to six months. This is in response to the recognized need for a safer alternative to ERCP. Repligen estimates that approximately 300,000 abdominal MRI procedures conducted in the U.S. and Europe each year may benefit from the use of SecreFlo.
Walter C. Herlihy, Ph.D., president and CEO of Repligen, said, “The commitment made by the FDA to expedite the review of the SecreFlo NDA underscores the need for safer, noninvasive methods for physicians to evaluate their patients with pancreatitis. If approved, we believe SecreFlo has the potential to improve pancreatic imaging and reduce the need for diagnostic endoscopy, to the benefit of patients and payers.”
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Based in Waltham, MA, Repligen is primarily focused on supplying products that aid in the manufacture of biologic drugs, and is using the accumulated expertise in this field to bring their SecreFlow product to market. The company also has two central nervous system rare disease programs in Phase 1 clinical trials. SecreFlow is a synthetic version of the naturally occurring human hormone secretin, produced in the small intestine and necessary during the human digestive process. SecreFlow can be used in patients to improve MRI quality when examining the pancreas.
SecreFlow is being developed as an alternative method of examining the pancreas, as opposed to endoscopic retrograde cholangiopancreatography (ERCP), an invasive procedure that has documented mortality risks. By granting SecreFlow priority review, the FDA will reduce the time it takes to deliver a decision on marketing approval from ten months to six months. This is in response to the recognized need for a safer alternative to ERCP. Repligen estimates that approximately 300,000 abdominal MRI procedures conducted in the U.S. and Europe each year may benefit from the use of SecreFlo.
Walter C. Herlihy, Ph.D., president and CEO of Repligen, said, “The commitment made by the FDA to expedite the review of the SecreFlo NDA underscores the need for safer, noninvasive methods for physicians to evaluate their patients with pancreatitis. If approved, we believe SecreFlo has the potential to improve pancreatic imaging and reduce the need for diagnostic endoscopy, to the benefit of patients and payers.”
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Socket Mobile, Inc. (SCKT) Announces Barcode Scanner for Apple Products
Socket Mobile, Inc. recently announced the upcoming debut of the Socket Bluetooth® Cordless Hand Scanner (CHS) 7Ci, a low-cost barcode scanner for the Apple iPad, iPhone, and iPod touch. The CHS 7Ci provides an affordable option for reading 1D barcodes using Apple devices.
Expanding upon Socket Mobile’s popular CHS Series 7 line, the Socket CHS 7Ci is a 1D imager-based barcode reader that can decode printed barcodes and barcodes displayed on device screens. It even features a special authentication chip to enable two-way communications with Apple devices, making SDK support for Apple iOS possible. The CHS 7Ci is also compatible with Android, BlackBerry, and Windows operating systems.
Lasse Styner Rostock, CEO of nSales, a mobile software developer that has deployed iOS applications with a 2D version of the CHS, remarked, “For sales force automation or field service, most of our customers only need to scan 1D barcodes. We welcome the new Socket CHS 7Ci as an economical option that will enable more of our customers to optimize their deployment of our iPad applications with high-performance barcode scanning.”
“Apple developers need a barcode scanner that supports two-way communications with iOS devices in order to enable data parsing, binary data, and other advanced features in their applications,” said Mike Gifford, executive vice president at Socket Mobile. “With the new Socket CHS 7Ci barcode scanner and our updated SocketScan 10 Software Development Kit, Apple developers can better target the vast majority of business barcode applications, which only involve 1D barcodes, while also offering a lower cost solution.”
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Expanding upon Socket Mobile’s popular CHS Series 7 line, the Socket CHS 7Ci is a 1D imager-based barcode reader that can decode printed barcodes and barcodes displayed on device screens. It even features a special authentication chip to enable two-way communications with Apple devices, making SDK support for Apple iOS possible. The CHS 7Ci is also compatible with Android, BlackBerry, and Windows operating systems.
Lasse Styner Rostock, CEO of nSales, a mobile software developer that has deployed iOS applications with a 2D version of the CHS, remarked, “For sales force automation or field service, most of our customers only need to scan 1D barcodes. We welcome the new Socket CHS 7Ci as an economical option that will enable more of our customers to optimize their deployment of our iPad applications with high-performance barcode scanning.”
“Apple developers need a barcode scanner that supports two-way communications with iOS devices in order to enable data parsing, binary data, and other advanced features in their applications,” said Mike Gifford, executive vice president at Socket Mobile. “With the new Socket CHS 7Ci barcode scanner and our updated SocketScan 10 Software Development Kit, Apple developers can better target the vast majority of business barcode applications, which only involve 1D barcodes, while also offering a lower cost solution.”
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Inovio Pharmaceuticals (INO) Reports Success in Skin Electroporation Technology Animal Studies Inovio Pharmaceuticals (INO) Reports Success in Skin Electroporation Technology Animal Studies
Inovio Pharmaceuticals Inc., engaged in the development of vaccines for the treatment of cancers and infectious diseases, today announced that its next-generation surface skin electroporation technology was successfully used to significantly enhance the delivery of small interfering RNA (siRNA) molecules to skin in animal studies. While the company has several ongoing human trials demonstrating the efficacy of its electroporation technology, this study marks the first time that this technology has been applied to the delivery of siRNA molecules.
Both preclinical and clinical studies have demonstrated electroporation as an effective physical delivery method with the capability to improve the expression and immunogenicity of DNA vaccines by up to 100-fold.
Inovio said the positive outcome of this study emphasizes the “far-reaching therapeutic potential” for the company’s electroporation technology.
“Perhaps the biggest hurdle in realizing the full potential of RNA-based therapies is the lack of proper and efficient delivery of siRNA molecules. This study supports the idea that Inovio’s proprietary electroporation technology can successfully deliver breakthrough RNA therapies with the same efficacy and safety in which we deliver DNA therapies,” Dr. J. Joseph Kim, president and CEO of Inovio, stated in the press release. “Most important, our delivery platform could pave the way for the development of targeted RNA-based therapies for diseases and conditions that are now considered untreatable.”
Inovio noted that in recent studies, siRNAs have demonstrated potential as novel therapeutics due to their ability to induce robust, sequence specific gene silencing in cells. The method of utilizing siRNA to induce RNA interference (RNAi) has potential as a therapeutic approach to treat many currently untreatable disorders, such as some cancers and many viral and genetic diseases.
Data from today’s announced study was published in the journal Molecular Therapy – Nucleic Acids in a paper titled, “Optimized in vivo transfer of small interfering RNA targeting dermal tissue using in vivo surface electroporation.”
For more information visit www.inovio.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Both preclinical and clinical studies have demonstrated electroporation as an effective physical delivery method with the capability to improve the expression and immunogenicity of DNA vaccines by up to 100-fold.
Inovio said the positive outcome of this study emphasizes the “far-reaching therapeutic potential” for the company’s electroporation technology.
“Perhaps the biggest hurdle in realizing the full potential of RNA-based therapies is the lack of proper and efficient delivery of siRNA molecules. This study supports the idea that Inovio’s proprietary electroporation technology can successfully deliver breakthrough RNA therapies with the same efficacy and safety in which we deliver DNA therapies,” Dr. J. Joseph Kim, president and CEO of Inovio, stated in the press release. “Most important, our delivery platform could pave the way for the development of targeted RNA-based therapies for diseases and conditions that are now considered untreatable.”
Inovio noted that in recent studies, siRNAs have demonstrated potential as novel therapeutics due to their ability to induce robust, sequence specific gene silencing in cells. The method of utilizing siRNA to induce RNA interference (RNAi) has potential as a therapeutic approach to treat many currently untreatable disorders, such as some cancers and many viral and genetic diseases.
Data from today’s announced study was published in the journal Molecular Therapy – Nucleic Acids in a paper titled, “Optimized in vivo transfer of small interfering RNA targeting dermal tissue using in vivo surface electroporation.”
For more information visit www.inovio.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
InVivo (NVIV) Announces Addition of Brian Hess, Award-winning and Seasoned Product Development Specialist
InVivo Therapeutics Holdings Corp., focused on polymer technology to develop treatments to improve function in individuals with spinal cord injury, today announced former Stryker biomaterials product development specialist Brian Hess as its director of product development.
In the role of director, Hess is responsible for the management, development, and maintenance of InVivo’s pipeline and portfolio of products. Hess will head the effort to transition InVivo technologies from research and development through clinical trials and into production manufacturing by developing specifications, protocols, and reports.
Hess’ most previous role was his eight-year tenure with Stryker, where he developed biomaterial technologies for the orthopedic market. He has led multiple product development teams through the FDA process, and was instrumental in developing HydroSetTM, an injectable calcium phosphate based bone substitute, from concept to product launch. HydroSet has become the market-leading bone scaffold, and in recognition of his success, Stryker awarded Hess and his team with “Best Technology” and “Best Team Synergy.”
Hess’ resume also includes the achievement of being named “Co-Innovator of the Year” in 2010 at Stryker for his work on a novel bone adhesive technology. Hess and his team spent the past three years demonstrating the technology’s feasibility and safety, growing his team to more than 25 engineers and scientists.
“We believe Brian’s past successes in the medical device industry will lead the commercialization of the three products we intend to have under review at FDA this year, as well as help to bring our portfolio of products for other neurological conditions successfully to the market in the coming years,” InVivo CEO Frank Reynolds stated in the press release.
For more information visit www.invivotherapeutics.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
In the role of director, Hess is responsible for the management, development, and maintenance of InVivo’s pipeline and portfolio of products. Hess will head the effort to transition InVivo technologies from research and development through clinical trials and into production manufacturing by developing specifications, protocols, and reports.
Hess’ most previous role was his eight-year tenure with Stryker, where he developed biomaterial technologies for the orthopedic market. He has led multiple product development teams through the FDA process, and was instrumental in developing HydroSetTM, an injectable calcium phosphate based bone substitute, from concept to product launch. HydroSet has become the market-leading bone scaffold, and in recognition of his success, Stryker awarded Hess and his team with “Best Technology” and “Best Team Synergy.”
Hess’ resume also includes the achievement of being named “Co-Innovator of the Year” in 2010 at Stryker for his work on a novel bone adhesive technology. Hess and his team spent the past three years demonstrating the technology’s feasibility and safety, growing his team to more than 25 engineers and scientists.
“We believe Brian’s past successes in the medical device industry will lead the commercialization of the three products we intend to have under review at FDA this year, as well as help to bring our portfolio of products for other neurological conditions successfully to the market in the coming years,” InVivo CEO Frank Reynolds stated in the press release.
For more information visit www.invivotherapeutics.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Tengasco, Inc. (TGC) Shows Strong 2011 Drilling Results and Provides Update on Reserves
Today, Tengasco, the independent oil and gas developer which has made quite a name for itself in the Central Kansas Uplift by employing advanced analytical, developmental, and production technologies, reported 2011 drilling results (period ending Dec. 31), updating reserves and offering a portrait of its logistical operations.
CEO of TGC, Jeff Bailey, was keen to point out the all-time annual company record set for gross production of some 246k barrels in 2011, which eclipsed previous records set in 2008 (238k barrels). Explaining that this feat was not attributable to any periodic records being set (daily, monthly, etc. as those records were all set in 2008), Bailey detailed how TGC was able to bring the reserve replacement percentage up to 137% via generic drilling, as reserve additions outpaced production declines. Reserves have been increased without additional acquisitions and drilling expenses were paid for largely from additional cash flow attributable to rising oil prices.
TGC looks forward to a 10-K filing for FY11 (ending Dec 31) and intends to issue a press release on earnings at the same time, offering a March 30 deadline for the release.
A technology portfolio that ranges from microseismic interpretation-driven 3D seismic imaging to state-of-the-art polymer techniques for increasing production/reserves, while lowering the cost/water requirements and improving overall long-term performance, has made TGC a force to be reckoned with. Of 26 wells drilled in 2011, 16 have come through as producers and 10 were dry holes. Polymer activities have been extremely helpful, delimiting backflow water volume and creating a physical barrier whose fluid dynamics enable increased access for the oil to enter the tubing.
TGC has obtained ($1.7M) requisite casing, tubing, and pump jacks already this year for use on the first 20 of 36 wells to be drilled in 2012, positioning for an aggressive program to be approached via cash flow and minimal use of the borrowing base (no third party drilling partners to be used). A dedicated rig has been contracted for the year with an option to add additional rigs should activity demand it, and the 2012 drilling program, while emphasizing Kansas operations, will also be going after targets on property in Tennessee (where TGC is also headquartered). TGC has already knocked out the first three wells (drilled/completed) in the program in Kansas and begun the fourth, with solid anticipation of the ability to secure a second rig to accelerate the process.
Wholly-owned TGC subsidiary Manufactured Methane Corp. (MMC) began selling electricity generated at its Carter Valley methane extraction site (reported Jan 25, sold under contract through the Tennessee Valley Authority Generation Partners program and including local distributor Holston Electric Cooperative, Inc.). MMC is thus able to gain an additional revenue stream while offsetting facility energy costs as methane production continues alongside electric generation. The added benefit of reduced oxygen input, combined with upgrades in the collection system, have yielded exceptional in-service time since Jan 25 for the facility as well.
Bailey pointed to the ability to simultaneously add reserve growth and gear up for an aggressive 2012 drilling schedule/budget as indicators of the health of TGC, offering the analysis that these 2011 results show a real comeback for the company, after doing no drilling in 2009 and being limited by cash availability in 2010. Bailey cited the benefit to investors of the 36-well drilling program for 2012 being all company-owned wells and shareholders should be very pleased with the upcoming 10-K and financials.
Ongoing tensions over Iran have already pushed some analysts to view this game of brinkmanship as potentially pushing prices at the pump in Europe 25% higher as soon as April, thanks to Iran freezing deliveries (and subsequently setting conditions on future oil sales) to British/French companies amid essentially stalled negotiations and tightening sanction talk. This is an unmistakable gesture from the market for domestic energy producers.
For more information, or to stay up to date with the latest developments at Tengasco, Inc., please visit the company’s website at: www.Tengasco.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
CEO of TGC, Jeff Bailey, was keen to point out the all-time annual company record set for gross production of some 246k barrels in 2011, which eclipsed previous records set in 2008 (238k barrels). Explaining that this feat was not attributable to any periodic records being set (daily, monthly, etc. as those records were all set in 2008), Bailey detailed how TGC was able to bring the reserve replacement percentage up to 137% via generic drilling, as reserve additions outpaced production declines. Reserves have been increased without additional acquisitions and drilling expenses were paid for largely from additional cash flow attributable to rising oil prices.
TGC looks forward to a 10-K filing for FY11 (ending Dec 31) and intends to issue a press release on earnings at the same time, offering a March 30 deadline for the release.
A technology portfolio that ranges from microseismic interpretation-driven 3D seismic imaging to state-of-the-art polymer techniques for increasing production/reserves, while lowering the cost/water requirements and improving overall long-term performance, has made TGC a force to be reckoned with. Of 26 wells drilled in 2011, 16 have come through as producers and 10 were dry holes. Polymer activities have been extremely helpful, delimiting backflow water volume and creating a physical barrier whose fluid dynamics enable increased access for the oil to enter the tubing.
TGC has obtained ($1.7M) requisite casing, tubing, and pump jacks already this year for use on the first 20 of 36 wells to be drilled in 2012, positioning for an aggressive program to be approached via cash flow and minimal use of the borrowing base (no third party drilling partners to be used). A dedicated rig has been contracted for the year with an option to add additional rigs should activity demand it, and the 2012 drilling program, while emphasizing Kansas operations, will also be going after targets on property in Tennessee (where TGC is also headquartered). TGC has already knocked out the first three wells (drilled/completed) in the program in Kansas and begun the fourth, with solid anticipation of the ability to secure a second rig to accelerate the process.
Wholly-owned TGC subsidiary Manufactured Methane Corp. (MMC) began selling electricity generated at its Carter Valley methane extraction site (reported Jan 25, sold under contract through the Tennessee Valley Authority Generation Partners program and including local distributor Holston Electric Cooperative, Inc.). MMC is thus able to gain an additional revenue stream while offsetting facility energy costs as methane production continues alongside electric generation. The added benefit of reduced oxygen input, combined with upgrades in the collection system, have yielded exceptional in-service time since Jan 25 for the facility as well.
Bailey pointed to the ability to simultaneously add reserve growth and gear up for an aggressive 2012 drilling schedule/budget as indicators of the health of TGC, offering the analysis that these 2011 results show a real comeback for the company, after doing no drilling in 2009 and being limited by cash availability in 2010. Bailey cited the benefit to investors of the 36-well drilling program for 2012 being all company-owned wells and shareholders should be very pleased with the upcoming 10-K and financials.
Ongoing tensions over Iran have already pushed some analysts to view this game of brinkmanship as potentially pushing prices at the pump in Europe 25% higher as soon as April, thanks to Iran freezing deliveries (and subsequently setting conditions on future oil sales) to British/French companies amid essentially stalled negotiations and tightening sanction talk. This is an unmistakable gesture from the market for domestic energy producers.
For more information, or to stay up to date with the latest developments at Tengasco, Inc., please visit the company’s website at: www.Tengasco.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Subscribe to:
Posts (Atom)